BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032. [PMID: 19880844 DOI: 10.1056/nejmoa0907845] [Cited by in Crossref: 1349] [Cited by in F6Publishing: 495] [Article Influence: 103.8] [Reference Citation Analysis]
Number Citing Articles
1 Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010;6:667-678. [PMID: 20877304 DOI: 10.1038/nrneph.2010.124] [Cited by in Crossref: 177] [Cited by in F6Publishing: 164] [Article Influence: 14.8] [Reference Citation Analysis]
2 Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol 2015;11:394-410. [PMID: 26055355 DOI: 10.1038/nrneph.2015.82] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 17.7] [Reference Citation Analysis]
3 Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 2011;80:288-94. [PMID: 21389972 DOI: 10.1038/ki.2011.49] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
4 Gómez-Puerta JA, Waikar SS, Solomon DH, Liu J, Alarcón GS, Winkelmayer WC, Costenbader KH. Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. J Clin Cell Immunol 2013;4:179. [PMID: 24672742 DOI: 10.4172/2155-9899.1000179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
5 Hou YH, Yang FJ, Lai IC, Lin SP, Wan TT, Chang RE. Effects of Erythropoietin Payment Policy on Cardiovascular Outcomes of Peritoneal Dialysis Patients: Observational Study. JMIR Med Inform 2020;8:e18716. [PMID: 33331829 DOI: 10.2196/18716] [Reference Citation Analysis]
6 Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, Califf RM, Szczech L. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrol Dial Transplant 2012;27:3606-14. [PMID: 22573238 DOI: 10.1093/ndt/gfs123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
7 Okumi M, Okabe Y, Unagami K, Kakuta Y, Iizuka J, Takagi T, Shirakawa H, Shimizu T, Omoto K, Ishida H, Nakamura M, Tanabe K; Japan Academic Consortium of Kidney Transplantation (JACK). The interaction between post-transplant anemia and allograft function in kidney transplantation: The Japan Academic Consortium of Kidney Transplantation-II study. Clin Exp Nephrol 2019;23:1066-75. [PMID: 31020441 DOI: 10.1007/s10157-019-01737-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Fanaroff AC, Califf RM, Harrington RA, Granger CB, McMurray JJV, Patel MR, Bhatt DL, Windecker S, Hernandez AF, Gibson CM, Alexander JH, Lopes RD. Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. J Am Coll Cardiol 2020;76:580-9. [PMID: 32731936 DOI: 10.1016/j.jacc.2020.05.069] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 23.0] [Reference Citation Analysis]
9 van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol 2020;21:88. [PMID: 32143582 DOI: 10.1186/s12882-020-01746-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
10 Garimella PS, Katz R, Patel KV, Kritchevsky SB, Parikh CR, Ix JH, Fried LF, Newman AB, Shlipak MG, Harris TB, Sarnak MJ; Health ABC Study. Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study. Circ Heart Fail 2016;9:e002124. [PMID: 26721912 DOI: 10.1161/CIRCHEARTFAILURE.115.002124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
11 Petrie MC, Jhund PS, Connolly E, Mark PB, MacDonald MR, Robertson M, Anker SD, Bhandari S, Farrington K, Kalra PA, Wheeler DC, Tomson CRV, Ford I, McMurray JJV, Macdougall IC; PIVOTAL Investigators and Committees. High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovasc Res 2021:cvab317. [PMID: 34875022 DOI: 10.1093/cvr/cvab317] [Reference Citation Analysis]
12 de Vries JK, Levin A, Loud F, Adler A, Mayer G, Pena MJ. Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives. Diabetes Obes Metab 2018;20 Suppl 3:24-9. [PMID: 30294955 DOI: 10.1111/dom.13412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Raichoudhury R, Spinowitz BS. Treatment of anemia in difficult-to-manage patients with chronic kidney disease. Kidney Int Suppl (2011) 2021;11:26-34. [PMID: 33777493 DOI: 10.1016/j.kisu.2020.12.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Abdel-Qadir HM, Chugh S, Lee DS. Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome. Int J Nephrol 2011;2011:351672. [PMID: 21660113 DOI: 10.4061/2011/351672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
15 Sato K, Kumagai N, Suzuki N. Alteration of the DNA Methylation Signature of Renal Erythropoietin-Producing Cells Governs the Sensitivity to Drugs Targeting the Hypoxia-Response Pathway in Kidney Disease Progression. Front Genet 2019;10:1134. [PMID: 31798631 DOI: 10.3389/fgene.2019.01134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Memon I, Norris KC, Bomback AS, Peralta C, Li S, Chen SC, McCullough PA, Whaley-Connell A, Jurkovitz C, Tamura MK, Saab G; for the Kidney Early Evaluation Program Investigators. The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. Cardiorenal Med 2013;3:120-7. [PMID: 23922552 DOI: 10.1159/000351229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, Kim SG, Lim SK, Vareesangthip K, Hung CC, Nangaku M; APSN HIF-PHI Recommendation Committee. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carlton) 2021;26:105-18. [PMID: 33222343 DOI: 10.1111/nep.13835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Sumida K, Diskin CD, Molnar MZ, Potukuchi PK, Thomas F, Lu JL, Rhee CM, Streja E, Yamagata K, Kalantar-Zadeh K, Kovesdy CP. Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis. Am J Nephrol 2017;46:397-407. [PMID: 29130991 DOI: 10.1159/000484356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl (2011) 2015;5:23-32. [PMID: 26097782 DOI: 10.1038/kisup.2015.6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
20 Allon M. Evidence-based cardiology in hemodialysis patients. J Am Soc Nephrol 2013;24:1934-43. [PMID: 24136920 DOI: 10.1681/ASN.2013060632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
21 Chen Y, Zelnick LR, Wang K, Katz R, Hoofnagle AN, Becker JO, Hsu CY, Go AS, Feldman HI, Mehta RC, Lash JP, Waikar SS, Hamm L, Chen J, Shafi T, Kestenbaum BR; CRIC Study Investigators. Association of tubular solute clearances with the glomerular filtration rate and complications of chronic kidney disease: the Chronic Renal Insufficiency Cohort study. Nephrol Dial Transplant 2020:gfaa057. [PMID: 33330914 DOI: 10.1093/ndt/gfaa057] [Reference Citation Analysis]
22 Voglhuber J, Ljubojevic-Holzer S, Abdellatif M, Sedej S. Targeting Cardiovascular Risk Factors Through Dietary Adaptations and Caloric Restriction Mimetics. Front Nutr 2021;8:758058. [PMID: 34660673 DOI: 10.3389/fnut.2021.758058] [Reference Citation Analysis]
23 Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D. Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. Kidney Med 2020;2:589-599.e1. [PMID: 33089137 DOI: 10.1016/j.xkme.2020.06.008] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Morosetti M, Gorini A, Costanzo AM, Cipriani S, Dominijanni S, Egan CG, Zappalà L, di Luzio Paparatti U. Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients). Int J Nephrol Renovasc Dis 2013;6:27-37. [PMID: 23550080 DOI: 10.2147/IJNRD.S38405] [Reference Citation Analysis]
25 Minnerup J, Wersching H, Schäbitz WR. EPO for stroke therapy - Is there a future for further clinical development? Exp Transl Stroke Med 2010;2:10. [PMID: 20459870 DOI: 10.1186/2040-7378-2-10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
26 Smith DH, Johnson ES, Blough DK, Thorp ML, Yang X, Petrik AF, Crispell KA. Predicting costs of care in heart failure patients. BMC Health Serv Res. 2012;12:434. [PMID: 23194470 DOI: 10.1186/1472-6963-12-434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
27 Iseki K. Nephrology for the people: Presidential Address at the 42nd Regional Meeting of the Japanese Society of Nephrology in Okinawa 2012. Clin Exp Nephrol 2013;17:480-7. [PMID: 23392566 DOI: 10.1007/s10157-013-0776-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, Nossuli AK, Lepore JJ, Aarup M, Cobitz AR. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J 2019;12:139-48. [PMID: 30746141 DOI: 10.1093/ckj/sfy014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
29 Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, Dekker FW. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol 2013;14:200. [PMID: 24066978 DOI: 10.1186/1471-2369-14-200] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
30 Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrol 2021;22:284. [PMID: 34419007 DOI: 10.1186/s12882-021-02491-y] [Reference Citation Analysis]
31 Noumi B, Teruya S, Salomon S, Helmke S, Maurer MS. Blood volume measurements in patients with heart failure and a preserved ejection fraction: implications for diagnosing anemia. Congest Heart Fail 2011;17:14-8. [PMID: 21272222 DOI: 10.1111/j.1751-7133.2010.00208.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
32 Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int 2011;80:663-9. [PMID: 21697811 DOI: 10.1038/ki.2011.188] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
33 Mendelssohn DC, McFarlane P. Conditionally funded field evaluations--a solution to the economic barriers limiting evidence generation in dialysis? Semin Dial 2011;24:556-9. [PMID: 21906167 DOI: 10.1111/j.1525-139X.2011.00970.x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Cserti-Gazdewich C. Shifting ground and gaps in transfusion support of patients with hematological malignancies. Hematology Am Soc Hematol Educ Program 2018;2018:553-60. [PMID: 30504357 DOI: 10.1182/asheducation-2018.1.553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Saunders MR, Lee H, Chin MH. Early winners and losers in dialysis center pay-for-performance. BMC Health Serv Res 2017;17:816. [PMID: 29216894 DOI: 10.1186/s12913-017-2764-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
36 Coyle M, Flaherty G, Jennings C. A critical review of chronic kidney disease as a risk factor for coronary artery disease. Int J Cardiol Heart Vasc 2021;35:100822. [PMID: 34179334 DOI: 10.1016/j.ijcha.2021.100822] [Reference Citation Analysis]
37 Huang JY, Hsu CW, Yang CW, Hung CC, Huang WH. Role of anuria in the relationship between indoxyl sulfate and anemia in peritoneal dialysis patients. Ther Clin Risk Manag 2016;12:1797-803. [PMID: 27932887 DOI: 10.2147/TCRM.S120012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Salgado Filho N, Lages JS, Brito DJA, Santos EJF, Dos Santos AM, de Souza FL, Mendes VGG, Silva GADS, Carneiro ECRL, Muniz MPR, Silva GEB, Sesso RCC. Variability in Hemoglobin Levels and the Factors Associated with Mortality in Hemodialysis Patients: A 78-Month Follow-Up Study. Int J Environ Res Public Health 2021;18:1078. [PMID: 33530448 DOI: 10.3390/ijerph18031078] [Reference Citation Analysis]
39 Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30:1665-1673. [PMID: 26238121 DOI: 10.1093/ndt/gfv302] [Cited by in Crossref: 150] [Cited by in F6Publishing: 138] [Article Influence: 21.4] [Reference Citation Analysis]
40 Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, Narita I, Reichel H, Port FK, Sukul N, Stengel B, Robinson BM, Massy ZA, Pisoni RL; CKDopps Investigators . Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J 2020;13:613-24. [PMID: 32905241 DOI: 10.1093/ckj/sfz091] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
41 Barratt J, Sulowicz W, Schömig M, Esposito C, Reusch M, Young J, Csiky B. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther 2021;38:5345-60. [PMID: 34523074 DOI: 10.1007/s12325-021-01903-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Rognant N, Pouliquen É, Fave S, Jolivot A, Laville M. Activité physique et maladie rénale chronique : quelles relations en 2013 ? Néphrologie & Thérapeutique 2014;10:86-93. [DOI: 10.1016/j.nephro.2013.09.006] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Wish JB. Treatment of Anemia in Kidney Disease: Beyond Erythropoietin. Kidney Int Rep 2021;6:2540-53. [PMID: 34622095 DOI: 10.1016/j.ekir.2021.05.028] [Reference Citation Analysis]
44 Kato S, Takahashi T, Miyata N, Roman RJ. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats. J Pharmacol Exp Ther 2020;372:166-74. [PMID: 31801803 DOI: 10.1124/jpet.119.262782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med 2012;3:25-31. [PMID: 22719216 DOI: 10.2147/JBM.S23270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
46 Fassett RG. Current and emerging treatment options for the elderly patient with chronic kidney disease. Clin Interv Aging 2014;9:191-9. [PMID: 24477220 DOI: 10.2147/CIA.S39763] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
47 Szczech L. Chronic kidney disease: Association between ESA use and stroke in patients with CKD. Nat Rev Nephrol 2011;7:365-6. [PMID: 21610681 DOI: 10.1038/nrneph.2011.70] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Dore DD, Swaminathan S, Gutman R, Trivedi AN, Mor V. Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes. J Clin Epidemiol 2013;66:S42-50. [PMID: 23849152 DOI: 10.1016/j.jclinepi.2013.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
49 Teehan G, Benz RL. An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost. Anemia 2011;2011:623673. [PMID: 21541213 DOI: 10.1155/2011/623673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
50 Tsujita M, Kosugi T, Goto N, Futamura K, Nishihira M, Okada M, Hiramitsu T, Narumi S, Uchida K, Takeda A, Morozumi K, Maruyama S, Watarai Y. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transplant 2019;34:1409-16. [PMID: 30561729 DOI: 10.1093/ndt/gfy365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
51 Bhandari S. Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care. NDT Plus 2011;4:i14-9. [PMID: 27045221 DOI: 10.1093/ndtplus/sfr044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
52 Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25:349-360. [PMID: 24158986 DOI: 10.1681/asn.2013050465] [Cited by in Crossref: 262] [Cited by in F6Publishing: 165] [Article Influence: 29.1] [Reference Citation Analysis]
53 van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol 2020;16:77-98. [PMID: 31554933 DOI: 10.1038/s41581-019-0197-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
54 Levin A, Perry T, De Zoysa P, Sigrist MK, Humphries K, Tang M, Djurdjev O. A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients. BMC Cardiovasc Disord 2014;14:156. [PMID: 25381032 DOI: 10.1186/1471-2261-14-156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
55 Rastogi A, Lerma EV. Anemia management for home dialysis including the new US public policy initiative. Kidney Int Suppl (2011) 2021;11:59-69. [PMID: 33777496 DOI: 10.1016/j.kisu.2020.12.005] [Reference Citation Analysis]
56 Nangaku M, Kondo K, Takabe S, Ueta K, Kaneko G, Otsuka M, Kawaguchi Y, Komatsu Y. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan. Ther Apher Dial 2021;25:642-53. [PMID: 33283981 DOI: 10.1111/1744-9987.13611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, Stevens V, Macdougall IC. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. Nephrology (Carlton) 2017;22:969-76. [PMID: 27699922 DOI: 10.1111/nep.12940] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
58 Belenfant X, Tabbi Anani W, Roland M, Mavel M, Laederich J. Traitement de l’insuffisance rénale chronique : stratégie thérapeutique. La Presse Médicale 2012;41:304-10. [DOI: 10.1016/j.lpm.2011.12.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Massicotte-Azarniouch D, Sood MM, Fergusson DA, Chassé M, Tinmouth A, Knoll GA. Blood Transfusion and Adverse Graft-related Events in Kidney Transplant Patients. Kidney Int Rep 2021;6:1041-9. [PMID: 33912754 DOI: 10.1016/j.ekir.2021.01.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Thorp ML, Smith DH, Johnson ES, Weiss JW, Vupputuri S, Petrik AF, Yang XH. Should measuring haemoglobin among chronic kidney disease patients be a performance measure? J Evid Based Med 2012;5:194-204. [PMID: 23557499 DOI: 10.1111/jebm.12005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Tanaka M, Ikuma M, Asakura W, Fujiwara Y. The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. Clin Pharmacol Ther 2021. [PMID: 33993499 DOI: 10.1002/cpt.2275] [Reference Citation Analysis]
62 Lee M, Kim SH, Jhee JH, Kim TY, Choi HY, Kim HJ, Park HC. Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis. Stem Cell Res Ther 2020;11:422. [PMID: 32993806 DOI: 10.1186/s13287-020-01932-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Richards KM, Spicer RA, Craig E, Kennedy SE. Prevalence and predictors of blood transfusion after pediatric kidney transplantation. Pediatr Nephrol 2018;33:2177-84. [PMID: 30006835 DOI: 10.1007/s00467-018-4017-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol 2018;33:227-38. [PMID: 28412770 DOI: 10.1007/s00467-017-3663-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
65 Hasegawa T, Zhao J, Fuller DS, Bieber B, Zee J, Morgenstern H, Hanafusa N, Nangaku M. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins. Am J Nephrol 2017;46:11-7. [PMID: 28564644 DOI: 10.1159/000477217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
66 Rahman A, Yamazaki D, Sufiun A, Kitada K, Hitomi H, Nakano D, Nishiyama A. A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. PLoS One 2018;13:e0192531. [PMID: 29415057 DOI: 10.1371/journal.pone.0192531] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
67 Tagawa M, Hamano T, Nishi H, Tsuchida K, Hanafusa N, Fukatsu A, Iseki K, Tsubakihara Y. Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. PLoS One 2014;9:e114678. [PMID: 25494334 DOI: 10.1371/journal.pone.0114678] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
68 Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014;29:1493-505. [PMID: 24005791 DOI: 10.1007/s00467-013-2557-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
69 Gaweda AE, Aronoff GR, Jacobs AA, Rai SN, Brier ME. Individualized anemia management reduces hemoglobin variability in hemodialysis patients. J Am Soc Nephrol 2014;25:159-66. [PMID: 24029429 DOI: 10.1681/ASN.2013010089] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
70 Kurella Tamura M, Yaffe K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int. 2011;79:14-22. [PMID: 20861818 DOI: 10.1038/ki.2010.336] [Cited by in Crossref: 172] [Cited by in F6Publishing: 141] [Article Influence: 14.3] [Reference Citation Analysis]
71 van Eps CL, Jeffriess L, Haluska B, Hawley CM, Coombes J, Matsumoto A, Jeffries JK, Johnson DW, Campbell SB, Isbel NM, Mudge DW, Marwick T. Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: an interventional cohort study. BMC Nephrol 2011;12:51. [PMID: 21962236 DOI: 10.1186/1471-2369-12-51] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
72 Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, Chertow GM. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. J Am Soc Nephrol 2017;28:1851-8. [PMID: 28082519 DOI: 10.1681/ASN.2016101053] [Cited by in Crossref: 64] [Cited by in F6Publishing: 29] [Article Influence: 12.8] [Reference Citation Analysis]
73 Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. [PMID: 29191165 DOI: 10.1186/s12882-017-0688-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
74 Khan I, Krishnan M, Kothawala A, Ashfaq A. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. BMC Nephrol 2011;12:22. [PMID: 21595975 DOI: 10.1186/1471-2369-12-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
75 Karaboyas A, Morgenstern H, Waechter S, Fleischer NL, Vanholder R, Jacobson SH, Sood MM, Schaubel DE, Inaba M, Pisoni RL, Robinson BM. Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. Clin Kidney J 2020;13:425-33. [PMID: 32699623 DOI: 10.1093/ckj/sfz065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
76 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
77 Reardon G, Pandya N, Bailey RA. Falls in nursing home residents receiving pharmacotherapy for anemia. Clin Interv Aging 2012;7:397-407. [PMID: 23055706 DOI: 10.2147/CIA.S34789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Shah RC, Schneider JA, Leurgans S, Bennett DA. Association of lower hemoglobin level and neuropathology in community-dwelling older persons. J Alzheimers Dis 2012;32:579-86. [PMID: 22869465 DOI: 10.3233/JAD-2012-120952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
79 Alagoz S, Dincer MT, Eren N, Bakir A, Pekpak M, Trabulus S, Seyahi N. Prevalence of anemia in predialysis chronic kidney disease: Is the study center a significant factor? PLoS One 2020;15:e0230980. [PMID: 32240223 DOI: 10.1371/journal.pone.0230980] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, Buemi M. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis. 2016;9:11-19. [PMID: 26893577 DOI: 10.2147/ijnrd.s78040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
81 Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int 2017;21 Suppl 1:S110-24. [PMID: 28449418 DOI: 10.1111/hdi.12567] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
82 Dixit VK, Ghosh JK, Lamtha SC, Kaushik P, Goyal SK, Behera MK, Singh N, Jain AK. Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India. J Clin Exp Hepatol 2014;4:101-5. [PMID: 25755547 DOI: 10.1016/j.jceh.2014.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
83 Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant 2015;30:187-96. [PMID: 24821751 DOI: 10.1093/ndt/gfu104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
84 Penny H, Leckström D, Goldsmith D. The Janus faces of ESAs: caveat Chimaera! Int Urol Nephrol 2013;45:761-7. [PMID: 22972568 DOI: 10.1007/s11255-012-0270-5] [Reference Citation Analysis]
85 Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Matsui A, Hirakata H. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. Am J Nephrol 2019;49:165-74. [PMID: 30699415 DOI: 10.1159/000496929] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
86 Rognoni C, Ortalda V, Biasi C, Gambaro G. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy. Adv Ther 2019;36:3253-64. [PMID: 31489572 DOI: 10.1007/s12325-019-01089-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
87 Zhang Y, Thamer M, Kshirsagar O, Cotter DJ. Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality? Health Serv Res 2013;48:949-71. [PMID: 23216415 DOI: 10.1111/1475-6773.12019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
88 Foley RN. Treatment of anemia in chronic kidney disease: known, unknown, and both. J Blood Med 2011;2:103-12. [PMID: 22287869 DOI: 10.2147/JBM.S13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Cantarelli C, Angeletti A, Cravedi P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am J Transplant 2019;19:2407-14. [PMID: 30903735 DOI: 10.1111/ajt.15369] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
90 Nangaku M, Kondo K, Kokado Y, Ueta K, Kaneko G, Tandai T, Kawaguchi Y, Komatsu Y. Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. J Am Soc Nephrol 2021:ASN. [PMID: 33883252 DOI: 10.1681/ASN.2020091311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
91 Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc 2012;1:8-15. [PMID: 23130114 DOI: 10.1161/JAHA.111.000059] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
92 Toto R, Petersen J, Berns JS, Lewis EF, Tran Q, Weir MR. A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. J Am Soc Nephrol 2021;32:469-78. [PMID: 33288629 DOI: 10.1681/ASN.2020050556] [Reference Citation Analysis]
93 Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J, Rossert J, Chertow GM, Tyan DB. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant 2013;28:2908-18. [PMID: 24009295 DOI: 10.1093/ndt/gft362] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
94 Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol 2021;32:737-55. [PMID: 33568383 DOI: 10.1681/ASN.2020081150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
95 Inrig JK, Bryskin SK, Patel UD, Arcasoy M, Szczech LA. Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors. BMC Nephrol 2011;12:67. [PMID: 22152013 DOI: 10.1186/1471-2369-12-67] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
96 Fishbane S, Roger SD, Martin E, Runyan G, O'Neil J, Qiu P, Locatelli F. Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. Clin J Am Soc Nephrol 2013;8:538-45. [PMID: 23243269 DOI: 10.2215/CJN.03440412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
97 Locatelli F, Mazzaferro S, Yee J. Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients. Clin J Am Soc Nephrol 2016;11:1269-80. [PMID: 27185524 DOI: 10.2215/CJN.00080116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
98 Provenzano R, Fishbane S, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Houser MT, Frison L, Houghton J, Little DJ, Peony Yu KH, Neff TB. Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis. Kidney Int Rep 2021;6:613-23. [PMID: 33732976 DOI: 10.1016/j.ekir.2020.12.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
99 Yu PH, Lin MY, Chiu YW, Lee JJ, Hwang SJ, Hung CC, Chen HC. Low serum iron is associated with anemia in CKD stage 1-4 patients with normal transferrin saturations. Sci Rep 2021;11:8343. [PMID: 33863963 DOI: 10.1038/s41598-021-87401-w] [Reference Citation Analysis]
100 Chen TK, Estrella MM, Astor BC, Greene T, Wang X, Grams ME, Appel LJ. Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK). Nephrol Dial Transplant 2015;30:1329-35. [PMID: 25817226 DOI: 10.1093/ndt/gfv037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
101 Musio F. Kidney Disease and Anemia in Elderly Patients. Clin Geriatr Med 2019;35:327-37. [PMID: 31230734 DOI: 10.1016/j.cger.2019.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Gregg LP, Jain N, Carmody T, Minhajuddin AT, Rush AJ, Trivedi MH, Hedayati SS. Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. Am J Nephrol 2019;50:37-47. [PMID: 31167183 DOI: 10.1159/000500668] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
103 Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol 2021;32:211-22. [PMID: 33272965 DOI: 10.1681/ASN.2020050595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
104 Gesualdo L, Combe C, Covic A, Dellanna F, Goldsmith D, London G, Mann JF, Zaoui P, Turner M, Muenzberg M, MacDonald K, Abraham I. Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). Int Urol Nephrol 2015;47:837-45. [PMID: 25894959 DOI: 10.1007/s11255-015-0970-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
105 Galle JC, Addison J, Suranyi MG, Claes K, Di Giulio S, Guerin A, Herlitz H, Kiss I, Farouk M, Manamley N, Wirnsberger G, Winearls C. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. Nephrol Dial Transplant 2016;31:2073-85. [PMID: 27190334 DOI: 10.1093/ndt/gfw047] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
106 Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Clin J Am Soc Nephrol. 2016;11:982-991. [PMID: 27094610 DOI: 10.2215/cjn.06890615] [Cited by in Crossref: 163] [Cited by in F6Publishing: 81] [Article Influence: 27.2] [Reference Citation Analysis]
107 Canney M, Birks P, Shao S, Parfrey P, Djurdjev O, Levin A. Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. Kidney Int Rep 2021;6:1130-40. [PMID: 33912762 DOI: 10.1016/j.ekir.2020.12.022] [Reference Citation Analysis]
108 Atkinson MA, Juraschek SP, Bertenthal MS, Detrick B, Furth SL, Miller ER 3rd. Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial. Pediatr Nephrol 2017;32:859-68. [PMID: 28013381 DOI: 10.1007/s00467-016-3563-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
109 Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 2011;31:113-20. [PMID: 21067252 DOI: 10.1007/BF03256938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
110 Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol 2019;14:28-39. [PMID: 30559105 DOI: 10.2215/CJN.02510218] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
111 Yessayan L, Yee J, Zasuwa G, Frinak S, Besarab A. Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study. BMC Nephrol 2014;15:119. [PMID: 25038614 DOI: 10.1186/1471-2369-15-119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
112 Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol 2016;27:3129-38. [PMID: 26917691 DOI: 10.1681/ASN.2015111232] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
113 Chen Y, Zelnick LR, Huber MP, Wang K, Bansal N, Hoofnagle AN, Paranji RK, Heckbert SR, Weiss NS, Go AS, Hsu CY, Feldman HI, Waikar SS, Mehta RC, Srivastava A, Seliger SL, Lash JP, Porter AC, Raj DS, Kestenbaum BR; CRIC Study Investigators. Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2021;78:226-235.e1. [PMID: 33421453 DOI: 10.1053/j.ajkd.2020.12.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Romanet T, Bedouch P, Zaoui P. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease]. Nephrol Ther 2019;15:104-9. [PMID: 30803900 DOI: 10.1016/j.nephro.2018.10.006] [Reference Citation Analysis]
115 Rivera RF, Guido D, Del Vecchio L, Corghi E, D'Amico M, Camerini C, Spotti D, Galassi A, Pozzi C, Cancarini G, Pontoriero G, Locatelli F. Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. J Nephrol 2016;29:673-81. [PMID: 26715394 DOI: 10.1007/s40620-015-0254-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
116 Tsui AK, Marsden PA, Mazer CD, Adamson SL, Henkelman RM, Ho JJ, Wilson DF, Heximer SP, Connelly KA, Bolz SS, Lidington D, El-Beheiry MH, Dattani ND, Chen KM, Hare GM. Priming of hypoxia-inducible factor by neuronal nitric oxide synthase is essential for adaptive responses to severe anemia. Proc Natl Acad Sci U S A 2011;108:17544-9. [PMID: 21976486 DOI: 10.1073/pnas.1114026108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
117 Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2016;68:873-81. [PMID: 27646425 DOI: 10.1053/j.ajkd.2016.07.022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
118 Zhang Y, Young JG, Thamer M, Hernán MA. Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies. Health Serv Res 2018;53:1900-18. [PMID: 28560811 DOI: 10.1111/1475-6773.12718] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
119 Winkelmayer WC, Walther CP. Roxadustat for CKD Anemia - Starting the Jigsaw Puzzle, What Will the Finished Picture Show? Kidney Int Rep 2021;6:559-61. [PMID: 33735328 DOI: 10.1016/j.ekir.2021.01.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
120 Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013;76:536-50. [PMID: 23802504 DOI: 10.1111/bcp.12195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
121 Karaboyas A, Morgenstern H, Fleischer NL, Vanholder RC, Dhalwani NN, Schaeffner E, Schaubel DE, Akizawa T, James G, Sinsakul MV, Pisoni RL, Robinson BM. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Med 2020;2:286-96. [PMID: 32734248 DOI: 10.1016/j.xkme.2020.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
122 Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol Int 2020;11:165-223. [PMID: 32802702 DOI: 10.1007/s13340-020-00439-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 19.5] [Reference Citation Analysis]
123 Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M. Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD. Kidney Int Rep 2021;6:1810-28. [PMID: 34307976 DOI: 10.1016/j.ekir.2021.04.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Sun CC, Vaja V, Chen S, Theurl I, Stepanek A, Brown DE, Cappellini MD, Weiss G, Hong CC, Lin HY, Babitt JL. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant 2013;28:1733-43. [PMID: 23345622 DOI: 10.1093/ndt/gfs584] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
125 Duronville JV, Diamantidis CJ. Medical safety in the care of the person with end-stage kidney disease. Semin Dial 2018;31:140-8. [PMID: 29315834 DOI: 10.1111/sdi.12672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Molnar MZ, Tabak AG, Alam A, Czira ME, Rudas A, Ujszaszi A, Beko G, Novak M, Kalantar-Zadeh K, Kovesdy CP, Mucsi I. Serum erythropoietin level and mortality in kidney transplant recipients. Clin J Am Soc Nephrol 2011;6:2879-86. [PMID: 21980181 DOI: 10.2215/CJN.05590611] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
127 Turenne MN, Cope EL, Porenta S, Mukhopadhyay P, Fuller DS, Pearson JM, Dahlerus C, Lantz B, Tentori F, Robinson BM. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? J Am Soc Nephrol 2015;26:754-64. [PMID: 25300289 DOI: 10.1681/ASN.2013111232] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
128 Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. Int J Nephrol 2020;2020:7692376. [PMID: 32665863 DOI: 10.1155/2020/7692376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
129 Garikapati K, Goh D, Khanna S, Echampati K. Uraemic Cardiomyopathy: A Review of Current Literature. Clin Med Insights Cardiol 2021;15:1179546821998347. [PMID: 33707979 DOI: 10.1177/1179546821998347] [Reference Citation Analysis]
130 Dubin RF, Deo R, Bansal N, Anderson AH, Yang P, Go AS, Keane M, Townsend R, Porter A, Budoff M, Malik S, He J, Rahman M, Wright J, Cappola T, Kallem R, Roy J, Sha D, Shlipak MG;  CRIC Study Investigators. Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort. Clin J Am Soc Nephrol. 2017;12:60-68. [PMID: 28062676 DOI: 10.2215/cjn.02700316] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
131 Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014;29:809-22. [PMID: 24523357 DOI: 10.1093/ndt/gft524] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
132 Roger SD. Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease. Clin Kidney J 2017;10:i9-i15. [PMID: 29225818 DOI: 10.1093/ckj/sfx100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
133 Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? J Am Soc Nephrol 2012;23:979-84. [PMID: 22460531 DOI: 10.1681/ASN.2011121185] [Cited by in Crossref: 120] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
134 Hayashi T, Uemura Y, Kumagai M, Kimpara M, Kanno H, Ohashi Y; MIRACLE-CKD Study Group. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study). Clin Exp Nephrol 2019;23:349-61. [PMID: 30291472 DOI: 10.1007/s10157-018-1649-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
135 Baker RJ, Mark PB, Patel RK, Stevens KK, Palmer N. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient. BMC Nephrol. 2017;18:174. [PMID: 28571571 DOI: 10.1186/s12882-017-0553-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 39] [Article Influence: 11.4] [Reference Citation Analysis]
136 Garlo K, Williams D, Lucas L, Wong R, Botler J, Abramson S, Parker MG. Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study. Medicine (Baltimore) 2015;94:e964. [PMID: 26107682 DOI: 10.1097/MD.0000000000000964] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
137 Coronado Daza JA, Cuchi GU. Gender Differences in Dose of Erythropoietin to Maintain Hemoglobin Target in Hemodialysis Patients. Indian J Nephrol 2019;29:160-5. [PMID: 31142961 DOI: 10.4103/ijn.IJN_124_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Fliser D, Dellanna F, Koch M, Wiggenhauser A; PRIMAVERA study group. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial. Nephrol Dial Transplant 2017;32:279-87. [PMID: 28186540 DOI: 10.1093/ndt/gfw418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
139 Cheng J, Kim J, Bieber SD, Lin E. Four years into MACRA: What has changed? Semin Dial 2020;33:26-34. [PMID: 31908062 DOI: 10.1111/sdi.12852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Muñoz M, Gómez-Ramírez S, Besser M, Pavía J, Gomollón F, Liumbruno GM, Bhandari S, Cladellas M, Shander A, Auerbach M. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017;15:422-37. [PMID: 28880842 DOI: 10.2450/2017.0113-17] [Cited by in F6Publishing: 30] [Reference Citation Analysis]
141 Braam B, Joles JA, Danishwar AH, Gaillard CA. Cardiorenal syndrome--current understanding and future perspectives. Nat Rev Nephrol 2014;10:48-55. [PMID: 24247284 DOI: 10.1038/nrneph.2013.250] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 8.7] [Reference Citation Analysis]
142 Singh AK. Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol 2012;8:616-8. [PMID: 23007621 DOI: 10.1038/nrneph.2012.218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
143 Bello NA, Lewis EF, Desai AS, Anand IS, Krum H, McMurray JJ, Olson K, Solomon SD, Swedberg K, van Veldhuisen DJ, Young JB, Pfeffer MA. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail 2015;17:1201-7. [PMID: 26423928 DOI: 10.1002/ejhf.412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
144 Atkinson MA, Kim JY, Roy CN, Warady BA, White CT, Furth SL. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol 2015;30:635-43. [PMID: 25380788 DOI: 10.1007/s00467-014-2991-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
145 Xu Y, Peng H, Ke B. α-klotho and anemia in patients with chronic kidney disease patients: A new perspective. Exp Ther Med 2017;14:5691-5. [PMID: 29250136 DOI: 10.3892/etm.2017.5287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
146 Theurl M, Nairz M, Schroll A, Sonnweber T, Asshoff M, Haschka D, Seifert M, Willenbacher W, Wilflingseder D, Posch W, Murphy AT, Witcher DR, Theurl I, Weiss G. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats. Haematologica 2014;99:1516-24. [PMID: 24895335 DOI: 10.3324/haematol.2013.099481] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
147 Mehrotra A. ESAs in transplant anemia: one size does not "fit all". J Am Soc Nephrol 2012;23:192-3. [PMID: 22241895 DOI: 10.1681/ASN.2011121220] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
148 Chan K, Moe SM, Saran R, Libby P. The cardiovascular-dialysis nexus: the transition to dialysis is a treacherous time for the heart. Eur Heart J 2021;42:1244-53. [PMID: 33458768 DOI: 10.1093/eurheartj/ehaa1049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
149 Nguyen NT, Maxwell AP, Donnelly M, O'Neill C. Prospective payment system and racial/ethnic disparities: a national retrospective observational study in anaemia complication among end-stage renal disease patients in the US. BMC Nephrol 2020;21:423. [PMID: 33023486 DOI: 10.1186/s12882-020-02081-4] [Reference Citation Analysis]
150 Lin E, MaCurdy T, Bhattacharya J. The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology. J Am Soc Nephrol 2017;28:2590-6. [PMID: 28754790 DOI: 10.1681/ASN.2017040407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
151 Brenner N, Kommalapati A, Ahsan M, Ganguli A. Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. J Nephrol 2020;33:267-75. [PMID: 31782127 DOI: 10.1007/s40620-019-00680-5] [Reference Citation Analysis]
152 Coyne DW, Singh HN, Smith WT, Giuseppi AC, Connarn JN, Sherman ML, Dellanna F, Malluche HH, Hruska KA. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. Kidney Int Rep 2019;4:1585-97. [PMID: 31891000 DOI: 10.1016/j.ekir.2019.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
153 Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond) 2014;11:525-35. [PMID: 25589951 DOI: 10.2217/cpr.14.46] [Cited by in Crossref: 82] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
154 Ahmadmehrabi S, Tang WHW. Hemodialysis-induced cardiovascular disease. Semin Dial 2018;31:258-67. [PMID: 29624739 DOI: 10.1111/sdi.12694] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
155 Wang Z, Sun W, Wei Z, Bao J, Song X, Li Y, Ji H, Zhang J, He C, Su B, Zhao W, Zhao C. Selective potassium uptake via biocompatible zeolite-polymer hybrid microbeads as promising binders for hyperkalemia. Bioact Mater 2021;6:543-58. [PMID: 32995679 DOI: 10.1016/j.bioactmat.2020.08.032] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis 2014;7:191-201. [PMID: 24899820 DOI: 10.2147/IJNRD.S65158] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
157 Birnie K, Caskey F, Ben-Shlomo Y, Sterne JA, Gilg J, Nitsch D, Tomson C. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. Nephrol Dial Transplant 2017;32:692-8. [PMID: 27190350 DOI: 10.1093/ndt/gfw043] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
158 Shen Y, Wang J, Yuan J, Yang L, Yu F, Wang X, Zhao MH, Zhang L, Zha Y; Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol 2021;22:64. [PMID: 33618679 DOI: 10.1186/s12882-021-02247-8] [Reference Citation Analysis]
159 El-Kannishy GM, Megahed AF, Tawfik MM, El-Said G, Zakaria RT, Mohamed NA, Taha EM, Ammar AA, Abd Eltawab AM, Sayed-Ahmed NA. Obesity may be erythropoietin dose-saving in hemodialysis patients. Kidney Res Clin Pract 2018;37:148-56. [PMID: 29971210 DOI: 10.23876/j.krcp.2018.37.2.148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
160 Ruiz-Laiglesia FJ, Garcés-Horna V, Formiga F. Comprehensive therapeutic approach for patients with heart failure and comorbidity. Rev Clin Esp (Barc) 2016;216:323-30. [PMID: 26552747 DOI: 10.1016/j.rce.2015.09.009] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
161 Becker KA, Jones JJ. An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat. Adv Ther 2018;35:5-11. [PMID: 29285707 DOI: 10.1007/s12325-017-0655-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Bello NA, Pfeffer MA, Skali H, McGill JB, Rossert J, Olson KA, Weinrauch L, Cooper ME, de Zeeuw D, Rossing P, McMurray JJ, Solomon SD. Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Res Care 2014;2:e000011. [PMID: 25452859 DOI: 10.1136/bmjdrc-2013-000011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
163 Shimamatsu K, Inamasu H. A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. Curr Ther Res Clin Exp 2013;74:5-8. [PMID: 24384988 DOI: 10.1016/j.curtheres.2012.12.001] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
164 Huang E, Bunnapradist S. Transplantation: Does anemia correction delay kidney allograft dysfunction? Nat Rev Nephrol 2012;8:196-8. [PMID: 22371244 DOI: 10.1038/nrneph.2012.39] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, Chan TM, Besarab A, Chou W, Bradley C, Eyassu M, Leong R, Lee TT, Saikali KG, Szczech L, Yu KP. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep 2021;6:624-35. [PMID: 33732977 DOI: 10.1016/j.ekir.2020.11.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
166 Shah R, Agarwal AK. Anemia associated with chronic heart failure: current concepts. Clin Interv Aging 2013;8:111-22. [PMID: 23403618 DOI: 10.2147/CIA.S27105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
167 Reda S, Motloch LJ, Hoppe UC. [Heart failure and anemia]. Herz 2013;38:597-603. [PMID: 23900390 DOI: 10.1007/s00059-013-3901-4] [Reference Citation Analysis]
168 Jie KE, van der Putten K, Wesseling S, Joles JA, Bergevoet MW, Pepers-de Kort F, Doevendans PA, Yasui Y, Liu Q, Verhaar MC, Gaillard CA, Braam B. Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure. PLoS One 2012;7:e41339. [PMID: 22957013 DOI: 10.1371/journal.pone.0041339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
169 Koo HM, Kim CH, Doh FM, Lee MJ, Kim EJ, Han JH, Han JS, Oh HJ, Park JT, Han SH, Yoo TH, Kang SW. The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis. PLoS One 2014;9:e87231. [PMID: 24505281 DOI: 10.1371/journal.pone.0087231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
170 Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clin J Am Soc Nephrol 2016;11:539-46. [PMID: 26614406 DOI: 10.2215/CJN.06370615] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
171 Izzedine H, Perazella MA. Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. Nephrol Dial Transplant 2015;30:1979-88. [PMID: 25648910 DOI: 10.1093/ndt/gfu387] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
172 Stack AG, Alghali A, Li X, Ferguson JP, Casserly LF, Cronin CJ, Reddan DN, Hussein W, Elsayed ME. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. Clin Kidney J 2018;11:99-107. [PMID: 29423209 DOI: 10.1093/ckj/sfx060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
173 Kwon O, Jang HM, Jung HY, Kim YS, Kang SW, Yang CW, Kim NH, Choi JY, Cho JH, Kim CD, Kim YL, Park SH; Clinical Research Center for End-Stage Renal Disease (CRC- ESRD) Investigators. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. PLoS One 2015;10:e0140241. [PMID: 26452232 DOI: 10.1371/journal.pone.0140241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
174 Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011) 2021;11:8-25. [PMID: 33777492 DOI: 10.1016/j.kisu.2020.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
175 Sepah YJ, Nguyen QD, Yamaguchi Y, Otsuka T, Majikawa Y, Reusch M, Akizawa T. Two Phase 3 Studies on Ophthalmological Effects of Roxadustat versus Darbepoetin. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.01.1045] [Reference Citation Analysis]
176 Noonan ML, Clinkenbeard EL, Ni P, Swallow EA, Tippen SP, Agoro R, Allen MR, White KE. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep 2020;8:e14434. [PMID: 32476270 DOI: 10.14814/phy2.14434] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
177 Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 2011;31:113-20. [PMID: 21067252 DOI: 10.1007/BF03256938] [Reference Citation Analysis]
178 Csiky B, Schömig M, Esposito C, Barratt J, Reusch M, Valluri U, Sulowicz W. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). Adv Ther 2021;38:5361-80. [PMID: 34537926 DOI: 10.1007/s12325-021-01904-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Crowe K, Quinn TJ, Mark PB, Findlay MD. "Is It Removed During Dialysis?"-Cognitive Dysfunction in Advanced Kidney Failure-A Review Article. Front Neurol 2021;12:787370. [PMID: 34925220 DOI: 10.3389/fneur.2021.787370] [Reference Citation Analysis]
180 Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Am J Nephrol 2017;45:380-8. [PMID: 28343225 DOI: 10.1159/000464476] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 14.6] [Reference Citation Analysis]
181 De Nicola L, Locatelli F, Conte G, Minutolo R. Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? Drugs 2014;74:159-68. [PMID: 24442793 DOI: 10.1007/s40265-013-0175-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
182 Qunibi WY. Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD. J Am Soc Nephrol 2015;26:2311-3. [PMID: 25736046 DOI: 10.1681/ASN.2015020135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
183 Harrison TG, Ronksley PE, James MT, Brindle ME, Ruzycki SM, Graham MM, McRae AD, Zarnke KB, McCaughey D, Ball CG, Dixon E, Hemmelgarn BR. The Perioperative Surgical Home, Enhanced Recovery After Surgery and how integration of these models may improve care for medically complex patients. Can J Surg 2021;64:E381-90. [PMID: 34296705 DOI: 10.1503/cjs.002020] [Reference Citation Analysis]
184 . Chapter 5: Referral to specialists and models of care. Kidney Int Suppl (2011) 2013;3:112-9. [PMID: 25599001 DOI: 10.1038/kisup.2012.68] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
185 de Zeeuw D. The future of Diabetic Kidney Disease management: reducing the unmet need. J Nephrol 2020;33:1163-9. [PMID: 32749580 DOI: 10.1007/s40620-020-00820-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Bello AK, Ribic CM, Cournoyer SH, Kiaii M, LeBlanc M, Poulin-Costello M, Churchill DN, Muirhead N. Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study. Can J Kidney Health Dis 2018;5:2054358118778564. [PMID: 29900001 DOI: 10.1177/2054358118778564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
187 Ward F, Holian J, Murray PT. Drug therapies to delay the progression of chronic kidney disease. Clin Med (Lond) 2015;15:550-7. [PMID: 26621944 DOI: 10.7861/clinmedicine.15-6-550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
188 Tarapan T, Musikatavorn K, Phairatwet P, Takkavatakarn K, Susantitaphong P, Eiam-Ong S, Tiranathanagul K. High sensitivity Troponin-I levels in asymptomatic hemodialysis patients. Ren Fail 2019;41:393-400. [PMID: 31132904 DOI: 10.1080/0886022X.2019.1603110] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
189 Gilbertson DT, Hu Y, Peng Y, Maroni BJ, Wetmore JB. Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study. Clin Nephrol 2017;88:254-65. [PMID: 28899480 DOI: 10.5414/CN109031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
190 Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM. Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. J Am Soc Nephrol 2014;25:819-26. [PMID: 24459231 DOI: 10.1681/ASN.2013060575] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
191 Slinin Y, Guo H, Gilbertson DT, Mau LW, Ensrud K, Rector T, Collins AJ, Ishani A. Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year. Clin J Am Soc Nephrol 2010;5:1574-81. [PMID: 20538835 DOI: 10.2215/CJN.01320210] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
192 Bataille S, Pelletier M, Sallée M, Berland Y, McKay N, Duval A, Gentile S, Mouelhi Y, Brunet P, Burtey S. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients. BMC Nephrol 2017;18:251. [PMID: 28747155 DOI: 10.1186/s12882-017-0668-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
193 Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107:647-655; quiz 655-656. [PMID: 20959896 DOI: 10.3238/arztebl.2010.0647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
194 Altincatal A, Macarthur RB, Teruya S, Helmke S, Maurer MS. A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction. Cardiovasc Ther 2013;31:92-9. [PMID: 21884028 DOI: 10.1111/j.1755-5922.2011.00295.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
195 Rainville N, Jachimowicz E, Wojchowski DM. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis. Expert Opin Ther Targets 2016;20:287-301. [PMID: 26419263 DOI: 10.1517/14728222.2016.1090975] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
196 Burrill DR, Vernet A, Collins JJ, Silver PA, Way JC. Targeted erythropoietin selectively stimulates red blood cell expansion in vivo. Proc Natl Acad Sci U S A 2016;113:5245-50. [PMID: 27114509 DOI: 10.1073/pnas.1525388113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
197 Khan UA, Garg AX, Parikh CR, Coca SG. Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis. PLoS One 2013;8:e71784. [PMID: 24009665 DOI: 10.1371/journal.pone.0071784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
198 Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 2016;17:97. [PMID: 27460779 DOI: 10.1186/s12882-016-0312-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
199 Martínez-Castelao A, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, Navarro-González JF, Montes R, De la Cruz-Troca JJ, Natarajan A, Batlle D. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol 2011;12:53. [PMID: 21970625 DOI: 10.1186/1471-2369-12-53] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
200 Yaseen M, Hassan W, Awad R, Ashqar B, Neyra J, Heister T, Malik O, El-Husseini A. Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era? Kidney Dis (Basel). 2019;5:69-80. [PMID: 31019921 DOI: 10.1159/000495139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
201 Vullaganti S, Goldsmith J, Teruya S, Alvarez J, Helmke S, Maurer MS. Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. J Geriatr Cardiol 2014;11:100-5. [PMID: 25009558 DOI: 10.3969/j.issn.1671-5411.2014.02.002] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
202 Coca SG. Is it AKI or nonrecovery of renal function that is important for long-term outcomes? Clin J Am Soc Nephrol 2013;8:173-6. [PMID: 23307878 DOI: 10.2215/CJN.12621212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
203 Ito H, Takeuchi Y, Ishida H, Otawa A, Shibayama A, Antoku S, Abe M, Mifune M, Togane M. Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus. J Diabetes Investig 2010;1:273-8. [PMID: 24843443 DOI: 10.1111/j.2040-1124.2010.00060.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
204 Li L, Chang A, Rostand SG, Hebert L, Appel LJ, Astor BC, Lipkowitz MS, Wright JT, Kendrick C, Wang X, Greene TH. A within-patient analysis for time-varying risk factors of CKD progression. J Am Soc Nephrol 2014;25:606-13. [PMID: 24231660 DOI: 10.1681/ASN.2013050464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
205 Zhang Y, Thamer M, Kaufman J, Cotter D, Hernán MA. Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. Med Care 2014;52 Suppl 3:S132-9. [PMID: 24561752 DOI: 10.1097/MLR.0b013e3182a53ca8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
206 Ben-Assa E, Shacham Y, Shashar M, Leshem-Rubinow E, Gal-Oz A, Schwartz IF, Schwartz D, Silverberg DS, Chernin G. Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study. Cardiorenal Med 2015;5:246-53. [PMID: 26648941 DOI: 10.1159/000433564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
207 Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol 2017;46:488-97. [PMID: 29241199 DOI: 10.1159/000485326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
208 Lu L, Zhijian H, Lei L, Wenchuan C, Zhimin Z. Berberine in Combination with Insulin Has Additive Effects on Titanium Implants Osseointegration in Diabetes Mellitus Rats. Evid Based Complement Alternat Med 2015;2015:824259. [PMID: 26783411 DOI: 10.1155/2015/824259] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
209 Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56. [PMID: 22921639 DOI: 10.1053/j.ajkd.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
210 Kalantar-Zadeh K, Cano NJ, Budde K, Chazot C, Kovesdy CP, Mak RH, Mehrotra R, Raj DS, Sehgal AR, Stenvinkel P. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol. 2011;7:369-384. [PMID: 21629229 DOI: 10.1038/nrneph.2011.60] [Cited by in Crossref: 114] [Cited by in F6Publishing: 97] [Article Influence: 10.4] [Reference Citation Analysis]
211 Borawski B, Malyszko JS, Kwiatkowska M, Malyszko J. Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today. J Clin Med 2021;10:4149. [PMID: 34575261 DOI: 10.3390/jcm10184149] [Reference Citation Analysis]
212 Livshits L, Barshtein G, Arbell D, Gural A, Levin C, Guizouarn H. Do We Store Packed Red Blood Cells under "Quasi-Diabetic" Conditions? Biomolecules 2021;11:992. [PMID: 34356616 DOI: 10.3390/biom11070992] [Reference Citation Analysis]
213 Budde K, Rath T, Kliem V. Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. J Transplant 2014;2014:179705. [PMID: 24883202 DOI: 10.1155/2014/179705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
214 Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012;60:390-401. [PMID: 22537421 DOI: 10.1053/j.ajkd.2012.03.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
215 Kim SM, Kim KM, Kwon SK, Kim HY. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease. J Korean Med Sci 2016;31:55-60. [PMID: 26770038 DOI: 10.3346/jkms.2016.31.1.55] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
216 Patel DM, Bose M, Cooper ME. Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. Int J Mol Sci 2020;21:E2218. [PMID: 32210089 DOI: 10.3390/ijms21062218] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
217 Ortiz A. Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. Clin Kidney J 2015;8:14-22. [PMID: 25713705 DOI: 10.1093/ckj/sfu142] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
218 Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne) 2021;8:642296. [PMID: 33842503 DOI: 10.3389/fmed.2021.642296] [Reference Citation Analysis]
219 Johnson AC, Becker K, Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 2010;299:F426-35. [PMID: 20504881 DOI: 10.1152/ajprenal.00248.2010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
220 Maoujoud O, Ahid S, Cherrah Y. The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. Int J Nephrol Renovasc Dis 2016;9:35-43. [PMID: 26966386 DOI: 10.2147/IJNRD.S96027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
221 Steppich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I; Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) Study Investigators. Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. BMC Cardiovasc Disord 2017;17:38. [PMID: 28109258 DOI: 10.1186/s12872-016-0464-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
222 Gardiner R, Roshan D, Brennan A, Connolly D, Murray S, Reddan D. Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. Ir J Med Sci 2019;188:223-30. [PMID: 29704093 DOI: 10.1007/s11845-018-1823-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
223 Grote Beverborg N, Verweij N, Klip IT, van der Wal HH, Voors AA, van Veldhuisen DJ, Gansevoort RT, Bakker SJ, van der Harst P, van der Meer P. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One 2015;10:e0125215. [PMID: 25915923 DOI: 10.1371/journal.pone.0125215] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
224 Pérez de Isla L, Bayes-Genis A, Sanchis J, Heras M. Summary of the clinical studies reported in the annual scientific sessions of the American Heart Association (Orlando, United States, November 14-18, 2009). Rev Esp Cardiol 2010;63:190-9. [PMID: 20109416 DOI: 10.1016/s1885-5857(10)70037-2] [Reference Citation Analysis]
225 Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Clin J Am Soc Nephrol 2020;15:608-15. [PMID: 32245781 DOI: 10.2215/CJN.08900719] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
226 Patel NS, Collino M, Yaqoob MM, Thiemermann C. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care 2011;1:40. [PMID: 21943500 DOI: 10.1186/2110-5820-1-40] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
227 Kaplan JM, Sharma N, Dikdan S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. Int J Mol Sci 2018;19:E389. [PMID: 29382128 DOI: 10.3390/ijms19020389] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
228 Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, Gandra SR, Solomon SD, Moustafa M, Macdougall IC. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011;6:845-855. [PMID: 21212421 DOI: 10.2215/cjn.06450710] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
229 Murashima M, Tanaka T, Kasugai T, Tomonari T, Ide A, Ono M, Mizuno M, Suzuki T, Hamano T. Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice. J Diabetes Investig 2021. [PMID: 34797947 DOI: 10.1111/jdi.13717] [Reference Citation Analysis]
230 Atkinson MA, Xiao R, Köttgen A, Wühl E, Wong CS, Wuttke M, Bayazit AK, Çalişkan S, Warady BA, Schaefer F, Furth SL. Genetic associations of hemoglobin in children with chronic kidney disease in the PediGFR Consortium. Pediatr Res 2019;85:324-8. [PMID: 30140068 DOI: 10.1038/s41390-018-0148-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Nassif ME, Patel JS, Shuster JE, Raymer DS, Jackups R Jr, Novak E, Gage BF, Prasad S, Silvestry SC, Ewald GA, LaRue SJ. Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 2015;3:146-53. [PMID: 25660839 DOI: 10.1016/j.jchf.2014.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
232 Helve J, Sund R, Haapio M, Groop PH, Grönhagen-Riska C, Finne P. Medication among patients with type 1 diabetes and predialytic renal disease. Diabetes Res Clin Pract 2014;103:510-5. [PMID: 24423442 DOI: 10.1016/j.diabres.2013.12.010] [Reference Citation Analysis]
233 Yilmaz M, Kircelli F, Artan AS, Oto O, Asci G, Gunestepe K, Basci A, Ok E, Sever MS. Naturally nonanemic dialysis patients: Who are they? Hemodial Int 2016;20:522-9. [PMID: 27147461 DOI: 10.1111/hdi.12425] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
234 Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631-1634. [PMID: 22935483 DOI: 10.1681/asn.2011111078] [Cited by in Crossref: 352] [Cited by in F6Publishing: 194] [Article Influence: 35.2] [Reference Citation Analysis]
235 Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol 2014; 3(4): 156-168 [PMID: 25374809 DOI: 10.5527/wjn.v3.i4.156] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
236 Na HY, Lee YK, Shin SK, Yang DH, Cheon W, Park JH, Lee JH, Song JO, Jo YI. A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis. Kidney Res Clin Pract 2014;33:210-6. [PMID: 26885479 DOI: 10.1016/j.krcp.2014.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
237 Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O. Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica 2018;103:1593-603. [PMID: 30076180 DOI: 10.3324/haematol.2018.192518] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
238 Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, Foote B, Hedman K, James G, Lopes AA, Massy Z, Reichel H, Sloand J, Waechter S, Wong MMY, Pecoits-Filho R. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep 2021;11:1784. [PMID: 33469061 DOI: 10.1038/s41598-020-79254-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
239 Wish JB, Anker SD, Butler J, Cases A, Stack AG, Macdougall IC. Iron Deficiency in CKD Without Concomitant Anemia. Kidney Int Rep 2021;6:2752-62. [PMID: 34805628 DOI: 10.1016/j.ekir.2021.07.032] [Reference Citation Analysis]
240 Piety NZ, Reinhart WH, Stutz J, Shevkoplyas SS. Optimal hematocrit in an artificial microvascular network. Transfusion 2017;57:2257-66. [PMID: 28681482 DOI: 10.1111/trf.14213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
241 Zelnick LR, Batacchi ZO, Ahmad I, Dighe A, Little RR, Trence DL, Hirsch IB, de Boer IH. Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease. Diabetes Care 2020;43:2379-87. [PMID: 32788282 DOI: 10.2337/dc20-0915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
242 Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013;24:1151-1158. [PMID: 23787911 DOI: 10.1681/asn.2012121164] [Cited by in Crossref: 108] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
243 Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci. 2014;15:10296-10333. [PMID: 24918289 DOI: 10.3390/ijms150610296] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
244 Pollock C, Neuen BL. Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes. Adv Chronic Kidney Dis 2021;28:298-308. [PMID: 34922686 DOI: 10.1053/j.ackd.2021.02.006] [Reference Citation Analysis]
245 Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One 2012;7:e43655. [PMID: 22952731 DOI: 10.1371/journal.pone.0043655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
246 Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2015;66:429-40. [PMID: 25935581 DOI: 10.1053/j.ajkd.2015.02.324] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
247 Sabe MA, Claggett B, Burdmann EA, Desai AS, Ivanovich P, Kewalramani R, Lewis EF, McMurray JJ, Olson KA, Parfrey P, Solomon SD, Pfeffer MA. Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). J Am Heart Assoc 2016;5:e002850. [PMID: 27108247 DOI: 10.1161/JAHA.115.002850] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
248 Perez-Villa F, Lafage-Proust MH, Gielen E, Ortiz A, Spasovski G, Argilés À. The renal patient seen by non-renal physicians: the kidney embedded in the 'milieu intérieur'. Clin Kidney J 2021;14:1077-87. [PMID: 34094517 DOI: 10.1093/ckj/sfaa234] [Reference Citation Analysis]
249 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
250 van der Weerd NC, Den Hoedt CH, Blankestijn PJ, Bots ML, van den Dorpel MA, Lévesque R, Mazairac AH, Nubé MJ, Penne EL, ter Wee PM, Grooteman MP; CONTRAST Investigators. Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST). PLoS One 2014;9:e94434. [PMID: 24743493 DOI: 10.1371/journal.pone.0094434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
251 Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, Boffa JJ, Flamant M, Vrtovsnik F, Stengel B, Froissart M; NephroTest Study Group. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 2012;7:35-42. [PMID: 22096037 DOI: 10.2215/CJN.04690511] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
252 Atkinson MA, White CT. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 2012;27:33-40. [PMID: 21400189 DOI: 10.1007/s00467-011-1832-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
253 Kuo KL, Hung SC, Tseng WC, Tsai MT, Liu JS, Lin MH, Hsu CC, Tarng DC; Taiwan Society of Nephrology Renal Registry Data System. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study. J Am Heart Assoc 2018;7:e009206. [PMID: 30371224 DOI: 10.1161/JAHA.118.009206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
254 Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015;:CD011122. [PMID: 26671531 DOI: 10.1002/14651858.CD011122.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
255 Salisch Sv, Klar M, Thurisch B, Bungert J, Dame C. Gata4 and Sp1 regulate expression of the erythropoietin receptor in cardiomyocytes. J Cell Mol Med 2011;15:1963-72. [PMID: 21029371 DOI: 10.1111/j.1582-4934.2010.01193.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
256 Arnold J, Sims D, Ferro CJ. Modulation of stroke risk in chronic kidney disease. Clin Kidney J 2016;9:29-38. [PMID: 26798458 DOI: 10.1093/ckj/sfv136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
257 Eswarappa M, Cantarelli C, Cravedi P. Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone. Front Immunol 2021;12:639370. [PMID: 33796104 DOI: 10.3389/fimmu.2021.639370] [Reference Citation Analysis]
258 Alabdan N, AlRuthia Y, Yates MED, Sales I, Finch CK, Hudson JQ. Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. PLoS One 2017;12:e0188390. [PMID: 29182650 DOI: 10.1371/journal.pone.0188390] [Reference Citation Analysis]
259 Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011;7:1055-66. [PMID: 22328891 DOI: 10.5114/aoms.2011.26620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
260 Raghban A, Kirsop J, Tang WHW. Prevention of Heart Failure in Patients with Chronic Kidney Disease. Curr Cardiovasc Risk Rep 2015;9. [DOI: 10.1007/s12170-014-0428-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
261 Bakker E, Mol PGM, Nabais J, Vetter T, Kretzler M, Nolan JJ, Mayer G, Sundgren AK, Heerspink HJL, Schiel A, de Vries ST, Gomez MF, Schulze F, de Zeeuw D, Pena MJ; BEAt-DKD Consortium. Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting. Front Pharmacol 2021;12:662642. [PMID: 34025424 DOI: 10.3389/fphar.2021.662642] [Reference Citation Analysis]
262 Ornt DB, Larive B, Rastogi A, Rashid M, Daugirdas JT, Hernandez A, Kurella Tamura M, Suri RS, Levin NW, Kliger AS; Frequent Hemodialysis Network Trial Group. Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) Trials. Nephrol Dial Transplant 2013;28:1888-98. [PMID: 23358899 DOI: 10.1093/ndt/gfs593] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
263 Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol 2011;6:1973-81. [PMID: 21784829 DOI: 10.2215/CJN.01050211] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
264 Park H, Liu X, Henry L, Harman J, Ross EA. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). BMC Nephrol 2018;19:318. [PMID: 30413150 DOI: 10.1186/s12882-018-1119-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
265 Robinson B, Fuller D, Zinsser D, Albert J, Gillespie B, Tentori F, Turenne M, Port F, Pisoni R. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis 2011;57:822-31. [PMID: 21530036 DOI: 10.1053/j.ajkd.2011.03.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
266 Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB. Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. Pharmacoecon Open 2019;3:463-78. [PMID: 30968369 DOI: 10.1007/s41669-019-0132-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
267 Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. Clin Exp Nephrol 2019;23:231-43. [PMID: 30182223 DOI: 10.1007/s10157-018-1632-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
268 Glaudet F, Hottelart C, Allard J, Allot V, Bocquentin F, Boudet R, Champtiaux B, Charmes JP, Ciobotaru M, Dickson Z, Essig M, Honoré P, Lacour C, Lagarde C, Manescu M, Peyronnet P, Poux JM, Rerolle JP, Rincé M, Couchoud C, Aldigier JC; REIN Limousin. The clinical status and survival in elderly dialysis: example of the oldest region of France. BMC Nephrol 2013;14:131. [PMID: 23800023 DOI: 10.1186/1471-2369-14-131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
269 Zakai NA, French B, Arnold AM, Newman AB, Fried LF, Robbins J, Chaves P, Cushman M. Hemoglobin decline, function, and mortality in the elderly: the cardiovascular health study. Am J Hematol 2013;88:5-9. [PMID: 23044913 DOI: 10.1002/ajh.23336] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
270 de Isla LP, Bayes-genis A, Sanchis J, Heras M. Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando, Estados Unidos, 14-18 de noviembre de 2009). Revista Española de Cardiología 2010;63:190-9. [DOI: 10.1016/s0300-8932(10)70037-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
271 Nguyen DL, Morgan TR. Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection. Clin Liver Dis (Hoboken) 2012;1:54-7. [PMID: 25688295 DOI: 10.1002/cld.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
272 Hayes W. Measurement of iron status in chronic kidney disease. Pediatr Nephrol 2019;34:605-13. [PMID: 29666917 DOI: 10.1007/s00467-018-3955-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
273 Whitman CB, Shreay S, Gitlin M, van Oijen MG, Spiegel BM. Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol 2013;8:1942-51. [PMID: 23929931 DOI: 10.2215/CJN.00160113] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
274 Shah AD, Nicholas O, Timmis AD, Feder G, Abrams KR, Chen R, Hingorani AD, Hemingway H. Threshold haemoglobin levels and the prognosis of stable coronary disease: two new cohorts and a systematic review and meta-analysis. PLoS Med 2011;8:e1000439. [PMID: 21655315 DOI: 10.1371/journal.pmed.1000439] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
275 Chan E, Hemmelgarn B, Klarenbach S, Manns B, Mustafa R, Nesrallah G, McQuillan R. Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question. Can J Kidney Health Dis 2017;4:2054358117695570. [PMID: 28321324 DOI: 10.1177/2054358117695570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
276 Gaweda AE, Jacobs AA, Aronoff GR, Brier ME. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
. Clin Nephrol 2018;90:276-85. [PMID: 30049300 DOI: 10.5414/CN109499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
277 Barrows IR, Raj DS. Janus Face of Coronary Artery Disease and Chronic Kidney Disease. J Am Heart Assoc 2016;5:e003596. [PMID: 27108249 DOI: 10.1161/JAHA.116.003596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
278 . Chapter 4: Red cell transfusion to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:311-6. [PMID: 25018951 DOI: 10.1038/kisup.2012.36] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
279 Demetz G, Laux M, Scherhag A, Hoekstra T, Suttorp MM, Dekker F, Roest M, Marcus-Kalish M, Mittelman M, Ott I. The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI. Thromb J. 2014;12:18. [PMID: 25228850 DOI: 10.1186/1477-9560-12-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
280 Etgen T. Kidney disease as a determinant of cognitive decline and dementia. Alzheimers Res Ther 2015;7:29. [PMID: 25780391 DOI: 10.1186/s13195-015-0115-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
281 Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, Fergusson DA, Gombotz H, Habler O, Monk TG. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106:13-22. [PMID: 21148637 DOI: 10.1093/bja/aeq361] [Cited by in Crossref: 320] [Cited by in F6Publishing: 275] [Article Influence: 29.1] [Reference Citation Analysis]
282 Fishbane S, Hirsch JS. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19. Am J Kidney Dis 2020;76:303-5. [PMID: 32479920 DOI: 10.1053/j.ajkd.2020.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
283 Cai T, Ke Q, Fang Y, Wen P, Chen H, Yuan Q, Luo J, Zhang Y, Sun Q, Lv Y, Zen K, Jiang L, Zhou Y, Yang J. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis 2020;11:390. [PMID: 32444604 DOI: 10.1038/s41419-020-2544-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
284 de Francisco AL. Individualizing anaemia therapy. NDT Plus 2010;3:519-26. [PMID: 25949459 DOI: 10.1093/ndtplus/sfq164] [Reference Citation Analysis]
285 Haase VH. Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. Exp Cell Res 2017;356:160-5. [PMID: 28483447 DOI: 10.1016/j.yexcr.2017.05.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
286 Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014;29:843-50. [PMID: 24170814 DOI: 10.1093/ndt/gft424] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
287 Shen JI, Norris KC. ESRD Payment Reform: First Do No Harm. J Am Soc Nephrol 2016;27:2924-6. [PMID: 27026369 DOI: 10.1681/ASN.2016020153] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
288 Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication Safety Principles and Practice in CKD. Clin J Am Soc Nephrol 2018;13:1738-46. [PMID: 29915131 DOI: 10.2215/CJN.00580118] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
289 Ookawara S, Ito K, Sasabuchi Y, Hayasaka H, Kofuji M, Uchida T, Horigome K, Imai S, Akikawa T, Wada N, Kiryu S, Imada S, Shindo M, Miyazawa H, Hirai K, Onishi Y, Shimoyama H, Watanabe A, Tabei K, Morishita Y. Associations of cerebral oxygenation with hemoglobin levels evaluated by near-infrared spectroscopy in hemodialysis patients. PLoS One 2020;15:e0236720. [PMID: 32776946 DOI: 10.1371/journal.pone.0236720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
290 . Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:299-310. [PMID: 25018950 DOI: 10.1038/kisup.2012.35] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
291 Shukla AM, Bose C, Karaduta OK, Apostolov EO, Kaushal GP, Fahmi T, Segal MS, Shah SV. Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. PLoS One 2015;10:e0139226. [PMID: 26414017 DOI: 10.1371/journal.pone.0139226] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
292 Hara T, Mukai H, Nakashima T, Sagara R, Furusho M, Miura S, Toyonaga J, Sugawara K, Takeda K. Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. Nephron Extra 2015;5:79-86. [PMID: 26648974 DOI: 10.1159/000441154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
293 Castillo N, García-García P, Rivero A, Jiménez-Sosa A, Macía M, Getino MA, Méndez ML, García-Pérez J, Navarro-González JF. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. BMC Nephrol 2012;13:60. [PMID: 22799577 DOI: 10.1186/1471-2369-13-60] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
294 Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. Clin J Am Soc Nephrol 2020;15:1155-65. [PMID: 32723804 DOI: 10.2215/CJN.16011219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
295 Toft G, Heide-Jørgensen U, van Haalen H, James G, Hedman K, Birn H, Christiansen CF, Thomsen RW. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol 2020;33:147-56. [PMID: 31587136 DOI: 10.1007/s40620-019-00652-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
296 Wang WN, Zhang WL, Zhou GY, Ma FZ, Sun T, Su SS, Xu ZG. Prediction of the molecular mechanisms and potential therapeutic targets for diabetic nephropathy by bioinformatics methods. Int J Mol Med 2016;37:1181-8. [PMID: 26986014 DOI: 10.3892/ijmm.2016.2527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
297 Diebold M, Kistler AD. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. BMC Nephrol 2019;20:76. [PMID: 30823916 DOI: 10.1186/s12882-019-1263-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
298 Akizawa T, Tsubakihara Y, Hirakata H, Watanabe Y, Hase H, Nishi S, Babazono T, Kumagai M, Katakura S, Uemura Y, Ohashi Y; JET-STREAM Study Group. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study. Clin Exp Nephrol 2016;20:885-95. [PMID: 26779906 DOI: 10.1007/s10157-015-1225-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
299 Xu Y, Alfaro-Magallanes VM, Babitt JL. Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders. Br J Haematol 2021;193:882-93. [PMID: 33316086 DOI: 10.1111/bjh.17252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
300 Borovka M, Teruya S, Alvarez J, Helmke S, Maurer MS. Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the heart failure with preserved ejection fraction (HFPEF) anemia trial. J Card Fail 2013;19:685-91. [PMID: 24125107 DOI: 10.1016/j.cardfail.2013.08.508] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
301 Pedrini LA, Zawada AM, Winter AC, Pham J, Klein G, Wolf M, Feuersenger A, Ruggiero P, Feliciani A, Barbieri C, Gauly A, Canaud B, Stuard S. Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients. PLoS One 2019;14:e0212795. [PMID: 30794672 DOI: 10.1371/journal.pone.0212795] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
302 Heuberger JAAC, Posthuma JJ, Ziagkos D, Rotmans JI, Daniels JMA, Gal P, Stuurman FE, Spronk HMH, Ten Cate H, Burggraaf J, Moerland M, Cohen AF. Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes. Eur J Appl Physiol 2020;120:1893-904. [PMID: 32537688 DOI: 10.1007/s00421-020-04419-0] [Reference Citation Analysis]
303 de Zeeuw D, Heerspink HJL. Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. Nephrol Dial Transplant 2020;35:ii38-42. [PMID: 32162661 DOI: 10.1093/ndt/gfaa013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
304 Thamer M, Zhang Y, Kshirsagar O, Cotter DJ, Kaufman JS. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database. Am J Kidney Dis 2014;64:706-13. [PMID: 25011692 DOI: 10.1053/j.ajkd.2014.05.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
305 Locatelli F, Del Vecchio L. A new paradigm in treating patients with chronic kidney disease and anaemia after a journey lasting more than 35 years. Nephrol Dial Transplant 2021;36:1559-63. [PMID: 34014305 DOI: 10.1093/ndt/gfab177] [Reference Citation Analysis]
306 Saglimbene V, Palmer SC, Craig JC, Ruospo M, Nicolucci A, Tonelli M, Johnson D, Lucisano G, Williams G, Valentini M, D'Alonzo D, Pellegrini F, Strippoli P, Salomone M, Santoro A, Maffei S, Hegbrant J, Tognoni G, Strippoli GF; CE-DOSE Study Investigators. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. PLoS One 2017;12:e0172735. [PMID: 28249030 DOI: 10.1371/journal.pone.0172735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
307 Khemiri H, Maresca M, Gestreau C. Carbamylated erythropoietin enhances mice ventilatory responses to changes in O2 but not CO2 levels. Respir Physiol Neurobiol 2016;232:1-12. [PMID: 27317882 DOI: 10.1016/j.resp.2016.06.002] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
308 Padhi S, Panda SK. Acquired Pure Red Cell Aplasia and Recombinant Erythropoietin. Indian J Nephrol 2021;31:331-5. [PMID: 34584346 DOI: 10.4103/ijn.IJN_229_20] [Reference Citation Analysis]
309 Al-Sharefi A, Mohammed A, Abdalaziz A, Jayasena CN. Androgens and Anemia: Current Trends and Future Prospects. Front Endocrinol (Lausanne) 2019;10:754. [PMID: 31798530 DOI: 10.3389/fendo.2019.00754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
310 Al-Ageel NA, Al-Aqeel SA, Abanmy NO, Alwakeel JS, Sabry A, Alsaran KA. Appropriateness of anemia management in hemodialysis patients. Saudi Pharm J 2012;20:85-91. [PMID: 23960781 DOI: 10.1016/j.jsps.2011.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
311 Chait Y, Kalim S, Horowitz J, Hollot CV, Ankers ED, Germain MJ, Thadhani RI. The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure. Hemodial Int 2016;20:392-8. [PMID: 26843352 DOI: 10.1111/hdi.12407] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
312 Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P, Rigatto C, Tangri N. Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2018;13:457-67. [PMID: 29463597 DOI: 10.2215/CJN.05390517] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
313 Motonishi S, Tanaka K, Ozawa T. Iron deficiency associates with deterioration in several symptoms independently from hemoglobin level among chronic hemodialysis patients. PLoS One 2018;13:e0201662. [PMID: 30071093 DOI: 10.1371/journal.pone.0201662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
314 Cappell KA, Shreay S, Cao Z, Varker HV, Paoli CJ, Gitlin M. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels. BMC Nephrol 2014;15:116. [PMID: 25015348 DOI: 10.1186/1471-2369-15-116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
315 Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig 2020;11:1020-76. [PMID: 33021749 DOI: 10.1111/jdi.13306] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 23.0] [Reference Citation Analysis]
316 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Reference Citation Analysis]
317 Wish JB. Perspective: Will We Ever Know the Optimal Hgb Level in ESRD? J Am Soc Nephrol 2018;29:2454-7. [PMID: 30185470 DOI: 10.1681/ASN.2018040363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
318 Herrington WG, Staplin N, Haynes R. Kidney disease trials for the 21st century: innovations in design and conduct. Nat Rev Nephrol 2020;16:173-85. [PMID: 31673162 DOI: 10.1038/s41581-019-0212-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
319 Fandrey J, Schödel J, Eckardt KU, Katschinski DM, Wenger RH. Now a Nobel gas: oxygen. Pflugers Arch 2019;471:1343-58. [PMID: 31754831 DOI: 10.1007/s00424-019-02334-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
320 Shayman JA. Challenges and opportunities in the development of therapeutics for chronic kidney disease. Transl Res 2015;165:482-7. [PMID: 25218118 DOI: 10.1016/j.trsl.2014.08.002] [Reference Citation Analysis]
321 Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015;26:1238-47. [PMID: 25542967 DOI: 10.1681/ASN.2014090922] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
322 Calvo JA, Miskulin DC, Meyer KB, Weiner DE. Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1621-7. [PMID: 20651155 DOI: 10.2215/CJN.02650310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
323 Meaney CJ, Karas S, Robinson B, Gaesser J, Forrest A, Krzyzanski W, Panesar M, Rao GG. Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. J Clin Pharmacol 2019;59:418-26. [PMID: 30412269 DOI: 10.1002/jcph.1330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
324 Zheng Q, Wang Y, Yang H, Sun L, Fu X, Wei R, Liu YN, Liu WJ. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:573645. [PMID: 33597868 DOI: 10.3389/fphar.2020.573645] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Kleikers PW, Hooijmans C, Göb E, Langhauser F, Rewell SS, Radermacher K, Ritskes-Hoitinga M, Howells DW, Kleinschnitz C, Schmidt HH. A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. Sci Rep 2015;5:13428. [PMID: 26310318 DOI: 10.1038/srep13428] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
326 Farshid A, Pathak R, Shadbolt B, Arnolda L, Talaulikar G. Diastolic function is a strong predictor of mortality in patients with chronic kidney disease. BMC Nephrol 2013;14:280. [PMID: 24359445 DOI: 10.1186/1471-2369-14-280] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
327 Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol 2019;30:1037-48. [PMID: 31015255 DOI: 10.1681/ASN.2018101007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
328 Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol. 2010;21:1765-1775. [PMID: 20798262 DOI: 10.1681/asn.2009101017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
329 Fiocchi EH, Cowgill LD, Brown DC, Markovich JE, Tucker S, Labato MA, Callan MB. The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs. J Vet Intern Med 2017;31:476-85. [PMID: 28256075 DOI: 10.1111/jvim.14681] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
330 Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int 2014;2014:937398. [PMID: 24959595 DOI: 10.1155/2014/937398] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
331 Naito T, Shun M, Nishimura H, Gibo T, Tosaka M, Kawashima M, Ando A, Ogawa T, Sanaka T, Nitta K. Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients. Clin Exp Nephrol 2021;25:1111-20. [PMID: 34106373 DOI: 10.1007/s10157-021-02071-2] [Reference Citation Analysis]
332 Akizawa T, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Yamamoto H. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. BMJ Open 2019;9:e026602. [PMID: 31203241 DOI: 10.1136/bmjopen-2018-026602] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
333 Lapchak PA. Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma! Expert Opin Investig Drugs 2010;19:1179-86. [PMID: 20828227 DOI: 10.1517/13543784.2010.517954] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
334 Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Ther Apher Dial 2021;25:575-85. [PMID: 33200512 DOI: 10.1111/1744-9987.13609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
335 Chand S, Ward DG, Ng ZY, Hodson J, Kirby H, Steele P, Rooplal I, Bantugon F, Iqbal T, Tselepis C, Drayson MT, Whitelegg A, Chowrimootoo M, Borrows R. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J Nephrol 2015;28:81-8. [PMID: 24687402 DOI: 10.1007/s40620-014-0083-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
336 Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, Mariat C. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant 2021:gfab191. [PMID: 34077510 DOI: 10.1093/ndt/gfab191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
337 Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. J Am Heart Assoc 2017;6:e004743. [PMID: 28554908 DOI: 10.1161/JAHA.116.004743] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
338 Theilade S, Claggett B, Hansen TW, Skali H, Lewis EF, Solomon SD, Parving HH, Pfeffer M, McMurray JJ, Rossing P; TREAT investigators. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). J Hum Hypertens 2016;30:46-52. [PMID: 25810068 DOI: 10.1038/jhh.2015.22] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
339 Yokoro M, Nakayama Y, Yamagishi SI, Ando R, Sugiyama M, Ito S, Yano J, Taguchi K, Kaida Y, Saigusa D, Kimoto M, Abe T, Ueda S, Fukami K. Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia. J Am Soc Nephrol 2017;28:2670-80. [PMID: 28600471 DOI: 10.1681/ASN.2016111184] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
340 Finkelstein FO, van Nooten F, Wiklund I, Trundell D, Cella D. Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. Health Qual Life Outcomes 2018;16:111. [PMID: 29855366 DOI: 10.1186/s12955-018-0933-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
341 Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med 2015;163:127-34. [PMID: 26054047 DOI: 10.7326/M14-1741] [Cited by in Crossref: 115] [Cited by in F6Publishing: 50] [Article Influence: 16.4] [Reference Citation Analysis]
342 Garcia Sanchez JJ, Thompson J, Scott DA, Evans R, Rao N, Sörstadius E, James G, Nolan S, Wittbrodt ET, Abdul Sultan A, Stefansson BV, Jackson D, Abrams KR. Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. Adv Ther 2021. [PMID: 34881414 DOI: 10.1007/s12325-021-02006-z] [Reference Citation Analysis]
343 Yang Q, Wang X. A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia. Int J Clin Pract 2021;75:e14011. [PMID: 33411966 DOI: 10.1111/ijcp.14011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Aapro M, Gascón P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J. Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. Front Pharmacol 2018;9:1498. [PMID: 30687083 DOI: 10.3389/fphar.2018.01498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
345 Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis 2015;66:196-205. [PMID: 25727384 DOI: 10.1053/j.ajkd.2014.12.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
346 Nayak-Rao S, Shenoy MP. Stroke in Patients with Chronic Kidney Disease…: How do we Approach and Manage it? Indian J Nephrol 2017;27:167-71. [PMID: 28553032 DOI: 10.4103/0971-4065.202405] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
347 Rivara MB, Mehrotra R. Is early initiation of dialysis harmful? Semin Dial 2014;27:250-2. [PMID: 24620732 DOI: 10.1111/sdi.12218] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
348 Tsuruya K, Torisu K, Yoshida H, Yamada S, Tanaka S, Tsuchimoto A, Eriguchi M, Fujisaki K, Masutani K, Kitazono T. Positive association of residual kidney function with hemoglobin level in patients on peritoneal dialysis independent of endogenous erythropoietin concentration. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0126-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
349 Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics 2014;8:155-67. [PMID: 24790409 DOI: 10.2147/BTT.S27578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
350 Del Vecchio L, Minutolo R. ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia? J Clin Med 2021;10:839. [PMID: 33670704 DOI: 10.3390/jcm10040839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
351 Swaminathan S, Mor V, Mehrotra R, Trivedi AN. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. Health Serv Res 2015;50:790-808. [PMID: 25355431 DOI: 10.1111/1475-6773.12252] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
352 Keri KC, Samji NS, Blumenthal S. Diabetic nephropathy: newer therapeutic perspectives. J Community Hosp Intern Med Perspect 2018;8:200-7. [PMID: 30181826 DOI: 10.1080/20009666.2018.1500423] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
353 Gu L, Lou Q, Wu H, Ouyang X, Bian R. Lack of association between anemia and renal disease progression in Chinese patients with type 2 diabetes. J Diabetes Investig 2016;7:42-7. [PMID: 26816600 DOI: 10.1111/jdi.12368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
354 Hedayati SS, Yalamanchili V, Finkelstein FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int 2012;81:247-55. [PMID: 22012131 DOI: 10.1038/ki.2011.358] [Cited by in Crossref: 152] [Cited by in F6Publishing: 125] [Article Influence: 13.8] [Reference Citation Analysis]
355 Anand I, Gupta P. How I treat anemia in heart failure. Blood 2020;136:790-800. [PMID: 31895946 DOI: 10.1182/blood.2019004004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
356 Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:783-796. [PMID: 23111861 DOI: 10.1055/s-0032-1328884] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
357 Biggar P, Kim GH. Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. Kidney Res Clin Pract 2017;36:209-23. [PMID: 28904872 DOI: 10.23876/j.krcp.2017.36.3.209] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
358 Wetmore JB, Li S, Yan H, Xu H, Peng Y, Sinsakul MV, Liu J, Gilbertson DT. Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. PLoS One 2018;13:e0203767. [PMID: 30256836 DOI: 10.1371/journal.pone.0203767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
359 Duong U, Kalantar-Zadeh K, Molnar MZ, Zaritsky JJ, Teitelbaum I, Kovesdy CP, Mehrotra R. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol 2012;35:198-208. [PMID: 22286821 DOI: 10.1159/000335685] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
360 Sibbel S, Maroni BJ, Brunelli SM. The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients. J Nephrol 2017;30:821-9. [PMID: 27644959 DOI: 10.1007/s40620-016-0350-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
361 Min HK, Oh YK, Choi KH, Lee KB, Park SK, Ahn C, Lee SW. Relationship between Cardiac Geometry and Serum Hepcidin in Chronic Kidney Disease: Analysis from the KNOW-CKD Study. J Korean Med Sci 2020;35:e2. [PMID: 31898431 DOI: 10.3346/jkms.2020.35.e2] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
362 Fell LH, Seiler-Mußler S, Sellier AB, Rotter B, Winter P, Sester M, Fliser D, Heine GH, Zawada AM. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. Nephrol Dial Transplant 2016;31:1835-45. [PMID: 27190361 DOI: 10.1093/ndt/gfw045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
363 Eisenga MF, De Jong MA, Van der Meer P, Leaf DE, Huls G, Nolte IM, Gaillard CAJM, Bakker SJL, De Borst MH. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. PLoS Med 2019;16:e1002818. [PMID: 31170159 DOI: 10.1371/journal.pmed.1002818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
364 Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med. 2012;3:77-85. [PMID: 22973119 DOI: 10.2147/jbm.s29204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
365 Hanna RM, Streja E, Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv Ther 2021;38:52-75. [PMID: 33123967 DOI: 10.1007/s12325-020-01524-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Lee J, Vernet A, Gruber NG, Kready KM, Burrill DR, Way JC, Silver PA. Rational engineering of an erythropoietin fusion protein to treat hypoxia. Protein Eng Des Sel 2021;34:gzab025. [PMID: 34725710 DOI: 10.1093/protein/gzab025] [Reference Citation Analysis]
367 Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29:2075-84. [PMID: 24891437 DOI: 10.1093/ndt/gfu201] [Cited by in Crossref: 149] [Cited by in F6Publishing: 127] [Article Influence: 18.6] [Reference Citation Analysis]
368 Diskin CJ. Towards Erythropoietin Equations That Estimate Oxygen Delivery rather than Static Hemoglobin Targets. Nephron Clin Pract 2012;120:c48-53. [DOI: 10.1159/000334627] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
369 Bhoopalan SV, Huang LJ, Weiss MJ. Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000Res 2020;9:F1000 Faculty Rev-1153. [PMID: 32983414 DOI: 10.12688/f1000research.26648.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
370 Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. Eur J Pharmacol 2021;912:174583. [PMID: 34678238 DOI: 10.1016/j.ejphar.2021.174583] [Reference Citation Analysis]
371 van der Mey D, Gerisch M, Jungmann NA, Kaiser A, Yoshikawa K, Schulz S, Radtke M, Lentini S. Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human. Basic Clin Pharmacol Toxicol 2021;128:511-24. [PMID: 33232579 DOI: 10.1111/bcpt.13538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
372 Holley JL. Age, eGFR, and CKD complications. Clin J Am Soc Nephrol 2011;6:2729-31. [PMID: 22157703 DOI: 10.2215/CJN.10771011] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
373 Choi MJ, Yee J. Erythropoiesis-Stimulating Agents and Cancer: Myth or Truth. Advances in Chronic Kidney Disease 2019;26:221-4. [DOI: 10.1053/j.ackd.2019.04.001] [Reference Citation Analysis]
374 Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, Sharma A, Maroni BJ, McCullough PA. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant 2019;34:90-9. [PMID: 29672740 DOI: 10.1093/ndt/gfy055] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
375 Xiong L, Zhang H, Guo Y, Song Y, Tao Y. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Front Pharmacol 2022;12:795214. [DOI: 10.3389/fphar.2021.795214] [Reference Citation Analysis]
376 Tangri N, Leslie WD. Erythropoietin in dialysis: blood, bones, and hormones. J Bone Miner Res 2021;36:1209-10. [PMID: 34087024 DOI: 10.1002/jbmr.4379] [Reference Citation Analysis]
377 Tan N, Liu X, Cai Y, Zhang S, Jian B, Zhou Y, Xu X, Ren S, Wei H, Song Y. The influence of direct laser metal sintering implants on the early stages of osseointegration in diabetic mini-pigs. Int J Nanomedicine 2017;12:5433-42. [PMID: 28814861 DOI: 10.2147/IJN.S138615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
378 Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. Clin J Am Soc Nephrol 2019;14:1701-10. [PMID: 31420350 DOI: 10.2215/CJN.01380219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
379 Musio F. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary. Expert Rev Hematol 2020;13:1175-88. [PMID: 33028115 DOI: 10.1080/17474086.2020.1830371] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
380 Xu Y, Evans M, Barany P, James G, Sjölander A, Carrero JJ. Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study. Clin Kidney J 2021;14:1780-8. [PMID: 34221385 DOI: 10.1093/ckj/sfaa213] [Reference Citation Analysis]
381 Michels WM, Jaar BG, Ephraim PL, Liu Y, Miskulin DC, Tangri N, Crews DC, Scialla JJ, Shafi T, Sozio SM, Bandeen-Roche K, Cook CJ, Meyer KB, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Intravenous iron administration strategies and anemia management in hemodialysis patients. Nephrol Dial Transplant 2017;32:173-81. [PMID: 27604984 DOI: 10.1093/ndt/gfw316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
382 . Chapter 3: Management of progression and complications of CKD. Kidney Int Suppl (2011) 2013;3:73-90. [PMID: 25598999 DOI: 10.1038/kisup.2012.66] [Cited by in Crossref: 64] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
383 Pan SY, Chiang WC, Chen PM, Liu HH, Chou YH, Lai TS, Lai CF, Chiu YL, Lin WY, Chen YM, Chu TS, Lin SL. Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. Sci Rep 2017;7:44013. [PMID: 28272424 DOI: 10.1038/srep44013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
384 Tang M, Zhu C, Yan T, Zhou Y, Lv Q, Chuan J. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat. Front Pharmacol 2021;12:658079. [PMID: 34276361 DOI: 10.3389/fphar.2021.658079] [Reference Citation Analysis]
385 Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One 2017;12:e0169117. [PMID: 28046068 DOI: 10.1371/journal.pone.0169117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
386 Nishiwaki H, Hasegawa T, Koiwa F, Hamano T, Masakane I. The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry. PLoS One 2019;14:e0210533. [PMID: 30629677 DOI: 10.1371/journal.pone.0210533] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Ryu JH, Koo TY, Ro H, Cho JH, Kim MG, Huh KH, Park JB, Lee S, Han S, Kim J, Oh KH, Yang J; KNOW-KT Study group. Better health-related quality of life in kidney transplant patients compared to chronic kidney disease patients with similar renal function. PLoS One 2021;16:e0257981. [PMID: 34606505 DOI: 10.1371/journal.pone.0257981] [Reference Citation Analysis]
388 Drozdz M, Weigert A, Silva F, Frazão J, Alsuwaida A, Krishnan M, Kleophas W, Brzosko S, Johansson FK, Jacobson SH. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis. BMC Nephrol 2019;20:5. [PMID: 30616548 DOI: 10.1186/s12882-018-1196-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
389 Martinez F, Pallet N. When erythropoietin meddles in immune affairs. J Am Soc Nephrol 2014;25:1887-9. [PMID: 24676638 DOI: 10.1681/ASN.2014030240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
390 Shroff GR, Carlson MD, Mathew RO. Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach. Eur Cardiol 2021;16:e48. [PMID: 34950244 DOI: 10.15420/ecr.2021.30] [Reference Citation Analysis]
391 Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med 2014;174:699-707. [PMID: 24589911 DOI: 10.1001/jamainternmed.2014.87] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
392 Schmidt LS, Petersen JZ, Vinberg M, Hageman I, Olsen NV, Kessing LV, Jørgensen MB, Miskowiak KW. Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. Trials 2018;19:234. [PMID: 29673379 DOI: 10.1186/s13063-018-2627-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
393 Lacquaniti A, Pasqualetti P, Tocco TCD, Campo S, Rovito S, Bucca M, Ragusa A, Monardo P. Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. Kidney Res Clin Pract 2020;39:334-43. [PMID: 32839355 DOI: 10.23876/j.krcp.20.015] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
394 Ginsberg JS, Zhan M, Diamantidis CJ, Woods C, Chen J, Fink JC. Patient-reported and actionable safety events in CKD. J Am Soc Nephrol 2014;25:1564-73. [PMID: 24556352 DOI: 10.1681/ASN.2013090921] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
395 Lundby C, Olsen NV. Effects of recombinant human erythropoietin in normal humans. J Physiol 2011;589:1265-71. [PMID: 20807784 DOI: 10.1113/jphysiol.2010.195917] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
396 He J, Shlipak M, Anderson A, Roy JA, Feldman HI, Kallem RR, Kanthety R, Kusek JW, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Wolf M, Zhang X, Raj D, Hamm L; CRIC (Chronic Renal Insufficiency Cohort) Investigators. Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. J Am Heart Assoc 2017;6:e005336. [PMID: 28515118 DOI: 10.1161/JAHA.116.005336] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
397 George S, McCann M. A nurse prescriber-led protocol for anaemia management in established haemodialysis patients: A retrospective study. J Clin Nurs 2020;29:2535-43. [PMID: 32267027 DOI: 10.1111/jocn.15275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
398 Winkelmayer WC, Liu J, Chertow GM, Tamura MK. Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med. 2011;171:1371-1378. [PMID: 21824952 DOI: 10.1001/archinternmed.2011.360] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
399 Del Fabbro P, Luthi JC, Carrera E, Michel P, Burnier M, Burnand B. Anemia and chronic kidney disease are potential risk factors for mortality in stroke patients: a historic cohort study. BMC Nephrol 2010;11:27. [PMID: 20950484 DOI: 10.1186/1471-2369-11-27] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
400 Scotté F, Launay-vacher V, Ray-coquard I. Traitements de l’anémie par carence martiale en oncologie. Bulletin du Cancer 2012;99:563-70. [DOI: 10.1684/bdc.2012.1579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
401 Warren JS, Zhao Y, Yung R, Desai A. Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011;57:424-33. [PMID: 21242808 DOI: 10.1097/FJC.0b013e31820d92fd] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
402 Wagner LA, Tata AL, Fink JC. Patient safety issues in CKD: core curriculum 2015. Am J Kidney Dis 2015;66:159-69. [PMID: 25987263 DOI: 10.1053/j.ajkd.2015.02.343] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
403 Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27:41-53. [PMID: 23291219 DOI: 10.1016/j.blre.2012.12.003] [Cited by in Crossref: 323] [Cited by in F6Publishing: 294] [Article Influence: 35.9] [Reference Citation Analysis]
404 Nair D, Wilson FP. Patient-Reported Outcome Measures for Adults With Kidney Disease: Current Measures, Ongoing Initiatives, and Future Opportunities for Incorporation Into Patient-Centered Kidney Care. Am J Kidney Dis 2019;74:791-802. [PMID: 31492487 DOI: 10.1053/j.ajkd.2019.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
405 Chang WX, Asakawa S, Toyoki D, Nemoto Y, Morimoto C, Tamura Y, Ota T, Shibata S, Fujigaki Y, Shen ZY, Uchida S. Predictors and the Subsequent Risk of End-Stage Renal Disease - Usefulness of 30% Decline in Estimated GFR over 2 Years. PLoS One 2015;10:e0132927. [PMID: 26177463 DOI: 10.1371/journal.pone.0132927] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
406 Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR. The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin. Wien Klin Wochenschr 2013;125:71-82. [PMID: 23299452 DOI: 10.1007/s00508-012-0311-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
407 Sico JJ, Myers LJ, Fenton BJ, Concato J, Williams LS, Bravata DM. Association between admission haematocrit and mortality among men with acute ischaemic stroke. Stroke Vasc Neurol 2018;3:160-8. [PMID: 30294472 DOI: 10.1136/svn-2018-000149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
408 Guedes M, Guetter CR, Erbano LHO, Palone AG, Zee J, Robinson BM, Pisoni R, de Moraes TP, Pecoits-Filho R, Baena CP. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol 2020;21:259. [PMID: 32641153 DOI: 10.1186/s12882-020-01912-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
409 Zachariah D, Kalra PR, Roberts PR. Sudden cardiac death in end stage renal disease: unlocking the mystery. J Nephrol 2015;28:133-41. [PMID: 25391630 DOI: 10.1007/s40620-014-0151-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
410 Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial). Clin Exp Nephrol 2018;22:78-84. [PMID: 28660446 DOI: 10.1007/s10157-017-1427-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
411 Minnerup J, Wersching H, Schäbitz WR. Erythropoietin for stroke treatment: dead or alive? Crit Care 2011;15:129. [PMID: 21418552 DOI: 10.1186/cc10057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
412 Toto RD. Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens 2010;19:444-9. [PMID: 20625290 DOI: 10.1097/MNH.0b013e32833ce6d5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
413 Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CF, Dekker FW. Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients. PLoS One 2013;8:e84848. [PMID: 24391978 DOI: 10.1371/journal.pone.0084848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
414 Price E, Artz AS, Barnhart H, Sapp S, Chelune G, Ershler WB, Walston JD, Gordeuk VR, Berger NA, Reuben D, Prchal J, Rao SV, Roy CN, Supiano MA, Schrier SL, Cohen HJ. A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200 ng/mL. Blood Cells Mol Dis 2014;53:221-30. [PMID: 25065855 DOI: 10.1016/j.bcmd.2014.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
415 Nakanishi T, Kuragano T, Kaibe S, Nagasawa Y, Hasuike Y. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 2012;16:819-26. [PMID: 23053592 DOI: 10.1007/s10157-012-0694-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
416 Song HY, Wei CM, Zhou WX, Hu HF, Wan QJ. Association between admission hemoglobin level and prognosis in patients with type 2 diabetes mellitus. World J Diabetes 2021; 12(11): 1917-1927 [PMID: 34888016 DOI: 10.4239/wjd.v12.i11.1917] [Reference Citation Analysis]
417 Kurella Tamura M, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, Messé SR, Sehgal AR, Kusek J, DeSalvo KB, Cornish-Zirker D, Cohan J, Seliger SL, Chertow GM, Go AS. Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study. Clin J Am Soc Nephrol 2011;6:248-56. [PMID: 20930087 DOI: 10.2215/CJN.02660310] [Cited by in Crossref: 83] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
418 Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol 2019;85:935-48. [PMID: 30677788 DOI: 10.1111/bcp.13877] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
419 Gibertoni D, Mandreoli M, Rucci P, Fantini MP, Rigotti A, Scarpioni R, Santoro A. Excess mortality attributable to chronic kidney disease. Results from the PIRP project. J Nephrol 2016;29:663-71. [PMID: 26498295 DOI: 10.1007/s40620-015-0239-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
420 Cho YI, Cho DJ. Hemorheology and microvascular disorders. Korean Circ J 2011;41:287-95. [PMID: 21779279 DOI: 10.4070/kcj.2011.41.6.287] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
421 Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM; IRON CORE Group. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017;92:1068-78. [PMID: 28612425 DOI: 10.1002/ajh.24820] [Cited by in Crossref: 137] [Cited by in F6Publishing: 111] [Article Influence: 27.4] [Reference Citation Analysis]
422 Inker LA, Tonelli M, Hemmelgarn BR, Levitan EB, Muntner P. Comparison of concurrent complications of CKD by 2 risk categorization systems. Am J Kidney Dis 2012;59:372-81. [PMID: 22113126 DOI: 10.1053/j.ajkd.2011.09.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
423 Stirnadel-Farrant HA, Luo J, Kler L, Cizman B, Jones D, Brunelli SM, Cobitz AR. Anemia and mortality in patients with nondialysis-dependent chronic kidney disease. BMC Nephrol 2018;19:135. [PMID: 29890958 DOI: 10.1186/s12882-018-0925-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
424 Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Steenkamp R, Tomson CRV, Wheeler DC, Winearls CG, Ford I; on behalf of the PIVOTAL Trial investigators. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. Am J Nephrol 2018;48:260-8. [PMID: 30304714 DOI: 10.1159/000493551] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
425 Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, Theurl I, Taub N, Jamnig C, Neurauter D, Huber LA, Tilg H, Moser PL, Weiss G. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity 2011;34:61-74. [PMID: 21256055 DOI: 10.1016/j.immuni.2011.01.002] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 11.5] [Reference Citation Analysis]
426 Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero JJ. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J 2020;13:821-7. [PMID: 33123358 DOI: 10.1093/ckj/sfaa054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
427 Cases A, Portolés J, Calls J, Martinez-Castelao A, Munar MA, Segarra A. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. Int Urol Nephrol 2014;46:1983-95. [PMID: 25118611 DOI: 10.1007/s11255-014-0800-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
428 Hamad A, Ezzat H, Latif Ghonimi TA, Ibrahim R, Ramadan F, Noor N, Yasin F, Ismail S, Al-Ali F. Effects of novel anemia nurse manager program on hemodialysis: a retrospective study from Qatar. Qatar Med J 2021;2021:46. [PMID: 34733708 DOI: 10.5339/qmj.2021.46] [Reference Citation Analysis]
429 Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2019;73:309-15. [PMID: 30578152 DOI: 10.1053/j.ajkd.2018.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
430 Alnaeeli M, Wang L, Piknova B, Rogers H, Li X, Noguchi CT. Erythropoietin in brain development and beyond. Anat Res Int 2012;2012:953264. [PMID: 22567318 DOI: 10.1155/2012/953264] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
431 Estrella MM, Jaar BG, Cavanaugh KL, Fox CH, Perazella MA, Soman SS, Howell E, Rocco MV, Choi MJ. Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers. BMC Nephrol. 2013;14:230. [PMID: 24152744 DOI: 10.1186/1471-2369-14-230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
432 Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol 2020;31:456-68. [PMID: 32041774 DOI: 10.1681/ASN.2019020213] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
433 Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA. Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study. BMC Nephrol 2014;15:154. [PMID: 25245951 DOI: 10.1186/1471-2369-15-154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
434 Koike K, Fukami K, Kawaguchi A, Shimamatsu K, Yamagishi S, Okuda S. Regulation of platelet count by erythropoiesis-stimulating agents - iron axis in hemodialysis patients. Int J Nephrol Renovasc Dis 2016;9:73-80. [PMID: 27099526 DOI: 10.2147/IJNRD.S98196] [Reference Citation Analysis]
435 Gluba-Brzózka A, Franczyk B, Olszewski R, Rysz J. The Influence of Inflammation on Anemia in CKD Patients. Int J Mol Sci 2020;21:E725. [PMID: 31979104 DOI: 10.3390/ijms21030725] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
436 Girndt M. [Diagnosis and treatment of chronic kidney disease]. Internist (Berl) 2017;58:243-56. [PMID: 28194476 DOI: 10.1007/s00108-017-0195-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
437 Toblli JE, Di Gennaro F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS One 2015;10:e0125528. [PMID: 25928811 DOI: 10.1371/journal.pone.0125528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
438 Dayimu A, Qian W, Fan B, Wang C, Li J, Wang S, Ji X, Zhou G, Zhang T, Xue F. Trajectories of Haemoglobin and incident stroke risk: a longitudinal cohort study. BMC Public Health 2019;19:1395. [PMID: 31660924 DOI: 10.1186/s12889-019-7752-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Harrison LE, Burton JO, Szeto CC, Li PK, McIntyre CW. Endotoxaemia in haemodialysis: a novel factor in erythropoetin resistance? PLoS One 2012;7:e40209. [PMID: 22768256 DOI: 10.1371/journal.pone.0040209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
440 Akizawa T, Iwasaki M, Otsuka T, Reusch M, Misumi T. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther 2019;36:1438-54. [PMID: 30953333 DOI: 10.1007/s12325-019-00943-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
441 de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492-2503. [PMID: 24206459 DOI: 10.1056/nejmoa1306033] [Cited by in Crossref: 581] [Cited by in F6Publishing: 305] [Article Influence: 64.6] [Reference Citation Analysis]
442 Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol 2014;89:88-96. [PMID: 24122955 DOI: 10.1002/ajh.23598] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 16.4] [Reference Citation Analysis]
443 Zhang L, Gong AG, Riaz K, Deng JY, Ho CM, Lin HQ, Dong TT, Lee YK, Tsim KW. A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide-induced anemic rats. FEBS Open Bio 2017;7:318-23. [PMID: 28286727 DOI: 10.1002/2211-5463.12146] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
444 Herrington W, Haynes R, Staplin N, Emberson J, Baigent C, Landray M. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial 2015;28:35-47. [PMID: 25040468 DOI: 10.1111/sdi.12281] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
445 Petersen JZ, Schmidt LS, Vinberg M, Jørgensen MB, Hageman I, Ehrenreich H, Knudsen GM, Kessing LV, Miskowiak KW. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Trials 2018;19:611. [PMID: 30400939 DOI: 10.1186/s13063-018-2995-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
446 Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, Zafar MU, Badimon JJ. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. Cardiovasc Drugs Ther 2021. [PMID: 34533692 DOI: 10.1007/s10557-021-07257-0] [Reference Citation Analysis]
447 Preziosi P. Faster drug approval: challenges for safety. Expert Opin Drug Saf 2016;15:1205-18. [PMID: 27308948 DOI: 10.1080/14740338.2016.1194825] [Reference Citation Analysis]
448 Hung SC, Kuo KL, Peng CH, Wu CH, Wang YC, Tarng DC. Association of fluid retention with anemia and clinical outcomes among patients with chronic kidney disease. J Am Heart Assoc 2015;4:e001480. [PMID: 25559015 DOI: 10.1161/JAHA.114.001480] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
449 Panwar B, Judd SE, Warnock DG, McClellan WM, Booth JN 3rd, Muntner P, Gutiérrez OM. Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults. Stroke 2016;47:2017-24. [PMID: 27382006 DOI: 10.1161/STROKEAHA.116.013077] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
450 Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant 2012;27:2303-11. [PMID: 22140136 DOI: 10.1093/ndt/gfr677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
451 Strippoli GF; Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE). Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010;11:70. [PMID: 20534124 DOI: 10.1186/1745-6215-11-70] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
452 Kandula P, Dobre M, Schold JD, Schreiber MJ, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6:50-62. [PMID: 20876671 DOI: 10.2215/cjn.03940510] [Cited by in Crossref: 204] [Cited by in F6Publishing: 83] [Article Influence: 17.0] [Reference Citation Analysis]
453 Mehrotra R, Perazella MA, Choi MJ. American Society of Nephrology Quiz and Questionnaire 2014: RRT. Clin J Am Soc Nephrol 2015;10:1100-6. [PMID: 25897000 DOI: 10.2215/CJN.01490215] [Reference Citation Analysis]
454 Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, Hirakata H. A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. Kidney Int Rep 2021;6:1840-9. [PMID: 34307978 DOI: 10.1016/j.ekir.2021.04.037] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
455 Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M, Chertow GM. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. J Am Soc Nephrol 2019;30:1495-504. [PMID: 31278194 DOI: 10.1681/ASN.2018101016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
456 Jung MY, Hwang SY, Hong YA, Oh SY, Seo JH, Lee YM, Park SW, Kim JS, Wang JK, Kim JY, Lee JE, Ko GJ, Pyo HJ, Kwon YJ. Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients. Kidney Res Clin Pract 2015;34:20-7. [PMID: 26484015 DOI: 10.1016/j.krcp.2014.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
457 Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, Glowacki F, Moulin B, Lebranchu Y, Touchard G. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23:360-368. [PMID: 22193388 DOI: 10.1681/asn.2011060546] [Cited by in Crossref: 68] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
458 Coyne DW, Goldsmith D, Macdougall IC. New options for the anemia of chronic kidney disease. Kidney Int Suppl (2011) 2017;7:157-63. [PMID: 30675430 DOI: 10.1016/j.kisu.2017.09.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
459 Maurin N. [The role of platelets in atherosclerosis, diabetes mellitus, and chronic kidney disease. An attempt at explaining the TREAT study results]. Med Klin (Munich) 2010;105:339-44. [PMID: 20503008 DOI: 10.1007/s00063-010-1062-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
460 Wagner LA, Fink JC. Ensuring Patient Safety During the Transition to ESRD. Semin Nephrol 2017;37:194-208. [PMID: 28410653 DOI: 10.1016/j.semnephrol.2016.12.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
461 Li X, Kshirsagar AV, Brookhart MA. Safety of intravenous iron in hemodialysis patients. Hemodial Int 2017;21 Suppl 1:S93-S103. [PMID: 28370957 DOI: 10.1111/hdi.12558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
462 Crugliano G, Serra R, Ielapi N, Battaglia Y, Coppolino G, Bolignano D, Bracale UM, Pisani A, Faga T, Michael A, Provenzano M, Andreucci M. Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?". Int J Mol Sci 2021;22:12590. [PMID: 34830468 DOI: 10.3390/ijms222212590] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 Manns BJ, Tonelli M. The new FDA labeling for ESA--implications for patients and providers. Clin J Am Soc Nephrol 2012;7:348-53. [PMID: 22266575 DOI: 10.2215/CJN.09960911] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
464 Staibano P, Perelman I, Lombardi J, Davis A, Tinmouth A, Carrier M, Stevenson C, Saidenberg E. Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. Kidney Dis (Basel) 2020;6:74-84. [PMID: 32309289 DOI: 10.1159/000502208] [Reference Citation Analysis]
465 McQuillan R, Jassal SV. Neuropsychiatric complications of chronic kidney disease. Nat Rev Nephrol 2010;6:471-9. [PMID: 20567247 DOI: 10.1038/nrneph.2010.83] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
466 Yuan Q, Zhang H, Deng T, Tang S, Yuan X, Tang W, Xie Y, Ge H, Wang X, Zhou Q, Xiao X. Role of Artificial Intelligence in Kidney Disease. Int J Med Sci 2020;17:970-84. [PMID: 32308551 DOI: 10.7150/ijms.42078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
467 Fukuhara S, Akizawa T, Morita S, Tsubakihara Y. Understanding measurements of vitality in patients with chronic kidney disease: connecting a quality-of-life scale to daily activities. PLoS One 2012;7:e40455. [PMID: 22808164 DOI: 10.1371/journal.pone.0040455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
468 Lagrèze WA, Küchlin S, Ihorst G, Grotejohann B, Beisse F, Volkmann M, Heinrich SP, Albrecht P, Ungewiss J, Wörner M, Hug MJ, Wolf S, Diem R; TONE study group. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurol 2021;20:991-1000. [PMID: 34800417 DOI: 10.1016/S1474-4422(21)00322-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Signore PE, Guo G, Wei Z, Zhang W, Lin A, Del Balzo U. A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. PLoS One 2021;16:e0255022. [PMID: 34339435 DOI: 10.1371/journal.pone.0255022] [Reference Citation Analysis]
470 Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 2014;29:2021-8. [PMID: 24794833 DOI: 10.1007/s00467-014-2820-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
471 Elstrott B, Khan L, Olson S, Raghunathan V, DeLoughery T, Shatzel JJ. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol 2020;104:153-61. [PMID: 31715055 DOI: 10.1111/ejh.13345] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
472 Drüeke TB, Massy ZA. Oral or intravenous iron for anemia correction in chronic kidney disease? Kidney Int 2015;88:673-5. [PMID: 26422625 DOI: 10.1038/ki.2015.189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
473 Sagheb MM, Fallahzadeh MA, Moaref A, Fallahzadeh MH, Dormanesh B. Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost. Nephrourol Mon 2016;8:e38495. [PMID: 27713870 DOI: 10.5812/numonthly.38495] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
474 Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab 2018;20:1369-76. [PMID: 29405626 DOI: 10.1111/dom.13245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
475 Patel NS, Nandra KK, Thiemermann C. Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. Crit Care 2012;16:229. [PMID: 22839413 DOI: 10.1186/cc11315] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
476 Susantitaphong P, Siribumrungwong M, Takkavatakarn K, Chongthanakorn K, Lieusuwan S, Katavetin P, Tiranathanagul K, Lekhyananda S, Tungsanga K, Vanichakarn S, Eiam-Ong S, Praditpornsilpa K. Effect of Maintenance Intravenous Iron Treatment on Erythropoietin Dose in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial. Can J Kidney Health Dis 2020;7:2054358120933397. [PMID: 32612843 DOI: 10.1177/2054358120933397] [Reference Citation Analysis]
477 Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 2018;14:291-312. [PMID: 29456246 DOI: 10.1038/nrneph.2018.9] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 29.0] [Reference Citation Analysis]
478 Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73:117-30. [PMID: 23338536 DOI: 10.1007/s40265-012-0002-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
479 Murphy F, Bennett L, Jenkins K. Managing anaemia of chronic kidney disease. Br J Nurs 2010;19:1281-2, 1284-6. [PMID: 21072014 DOI: 10.12968/bjon.2010.19.20.79681] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
480 Kim T, Rhee CM, Streja E, Obi Y, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K. Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. Nephrol Dial Transplant 2017;32:370-7. [PMID: 28186572 DOI: 10.1093/ndt/gfw012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
481 Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol 2017;18:14. [PMID: 28077085 DOI: 10.1186/s12882-017-0438-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
482 Besarab A, Zeig SN, Martin ER, Pergola PE, Whittier FC, Zabaneh RI, Schiller B, Mayo M, Francisco CA, Polu KR, Duliege AM. An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients. BMC Nephrol 2012;13:95. [PMID: 22935486 DOI: 10.1186/1471-2369-13-95] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
483 Wang B, Yin Q, Han YC, Wu M, Li ZL, Tu Y, Zhou LT, Wei Q, Liu H, Tang RN, Cao JY, Lv LL, Liu BC. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Ren Fail 2020;42:912-25. [PMID: 32869703 DOI: 10.1080/0886022X.2020.1811121] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
484 Shah BN, Greaves K. The cardiorenal syndrome: a review. Int J Nephrol 2010;2011:920195. [PMID: 21253529 DOI: 10.4061/2011/920195] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
485 Briet M, Barhoumi T, Mian MO, Sierra C, Boutouyrie P, Davidman M, Bercovitch D, Nessim SJ, Frisch G, Paradis P, Lipman ML, Schiffrin EL. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc 2013;2:e000128. [PMID: 23584809 DOI: 10.1161/JAHA.113.000128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
486 Locatelli F. Iron treatment and the TREAT trial. NDT Plus 2011;4:i3-5. [PMID: 27046442 DOI: 10.1093/ndtplus/sfr041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
487 Masson P, Kelly PJ, Craig JC, Lindley RI, Webster AC. Risk of Stroke in Patients with ESRD. Clin J Am Soc Nephrol 2015;10:1585-92. [PMID: 26209158 DOI: 10.2215/CJN.12001214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
488 McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail 2013;15:334-41. [PMID: 23329651 DOI: 10.1093/eurjhf/hfs204] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
489 Kalantar-Zadeh K. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am J Nephrol 2017;45:235-47. [PMID: 28142147 DOI: 10.1159/000455387] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
490 Valliant A, Hofmann RM. Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. Int J Nanomedicine 2013;8:3297-307. [PMID: 24023516 DOI: 10.2147/IJN.S44944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
491 Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011;22:358-65. [PMID: 21164028 DOI: 10.1681/ASN.2010020173] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
492 Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res 2014;6:319-30. [PMID: 25050070 DOI: 10.2147/CEOR.S46930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
493 Erlingmark J, Hedström M, Lindberg M. NURSE STAFFING AND RENAL ANAEMIA OUTCOMES IN HAEMODIALYSIS CARE. J Ren Care 2016;42:185-9. [PMID: 27364918 DOI: 10.1111/jorc.12167] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
494 Kovesdy CP, Kalantar-Zadeh K. Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis 2012;19:11-8. [PMID: 22364796 DOI: 10.1053/j.ackd.2011.09.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
495 Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J 2016;9:260-7. [PMID: 26985378 DOI: 10.1093/ckj/sfv142] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
496 St Peter WL, Guo H, Kabadi S, Gilbertson DT, Peng Y, Pendergraft T, Li S. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol 2018;19:67. [PMID: 29544446 DOI: 10.1186/s12882-018-0861-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
497 Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open 2019;9:e026704. [PMID: 31203242 DOI: 10.1136/bmjopen-2018-026704] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
498 McMahon LP, Cai MX, Baweja S, Holt SG, Kent AB, Perkovic V, Leikis MJ, Becker GJ. Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. BMC Nephrol 2012;13:40. [PMID: 22702540 DOI: 10.1186/1471-2369-13-40] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
499 Pirkle JL Jr, Paoli CJ, Russell G, Petersen J, Burkart J. Hemoglobin stability and patient compliance with darbepoetin alfa in peritoneal dialysis patients after the implementation of the prospective payment system. Clin Ther 2014;36:1665-74. [PMID: 25256386 DOI: 10.1016/j.clinthera.2014.08.011] [Reference Citation Analysis]
500 Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 2013;8:e78930. [PMID: 24223866 DOI: 10.1371/journal.pone.0078930] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
501 McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012;14:341-3. [PMID: 22431404 DOI: 10.1093/eurjhf/hfs033] [Cited by in Crossref: 694] [Cited by in F6Publishing: 423] [Article Influence: 69.4] [Reference Citation Analysis]
502 Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, Jardine MJ, Okpechi IG, Pannu N, Stengel B, Tuttle KR, Uhlig K, Levey AS. Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney Int Suppl (2011) 2017;7:138-44. [PMID: 30675428 DOI: 10.1016/j.kisu.2017.07.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
503 Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392-400. [PMID: 22290531 DOI: 10.1002/ajh.23110] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 11.4] [Reference Citation Analysis]
504 Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012;82:235-41. [PMID: 22437411 DOI: 10.1038/ki.2012.76] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
505 Drüeke TB, Massy ZA. Erythropoiesis-Stimulating Agents and Mortality. J Am Soc Nephrol 2019;30:907-8. [PMID: 31015256 DOI: 10.1681/ASN.2019030266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
506 Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag 2011;7:103-13. [PMID: 21479141 DOI: 10.2147/TCRM.S17536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
507 Holdstock L, Cizman B, Meadowcroft AM, Biswas N, Johnson BM, Jones D, Kim SG, Zeig S, Lepore JJ, Cobitz AR. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J 2019;12:129-38. [PMID: 30746140 DOI: 10.1093/ckj/sfy013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
508 Thompson A, Cattran DC, Blank M, Nachman PH. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. J Am Soc Nephrol 2015;26:2930-7. [PMID: 26078365 DOI: 10.1681/ASN.2015010091] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
509 Erez D, Shefler C, Roitman E, Levy S, Dovrish Z, Ellis M, Twito O. Anemia in Diabetes and Pre-Diabetes with Normal Kidney Function: Prevalence and Clinical Outcomes. Endocr Pract 2021:S1530-891X(21)01290-8. [PMID: 34742906 DOI: 10.1016/j.eprac.2021.10.005] [Reference Citation Analysis]
510 Toto RD. Bardoxolone-the Phoenix? J Am Soc Nephrol 2018;29:360-1. [PMID: 29371416 DOI: 10.1681/ASN.2017121317] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
511 Rabelink TJ, de Zeeuw D. The glycocalyx--linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol 2015;11:667-76. [PMID: 26460356 DOI: 10.1038/nrneph.2015.162] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 11.0] [Reference Citation Analysis]
512 Pavenski K, Hare GM, Mazer CD. Erythropoietic neuroprotection: Holy Grail or potential to fail? Intensive Care Med 2011;37:1403-5. [PMID: 21779850 DOI: 10.1007/s00134-011-2305-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
513 Slotki I, Cabantchik ZI. The Labile Side of Iron Supplementation in CKD. J Am Soc Nephrol 2015;26:2612-9. [PMID: 25999405 DOI: 10.1681/ASN.2015010052] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
514 Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med 2013;126:541.e1-541.e14. [PMID: 23597800 DOI: 10.1016/j.amjmed.2012.11.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
515 Miskulin DC, Zhou J, Tangri N, Bandeen-Roche K, Cook C, Ephraim PL, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Trends in anemia management in US hemodialysis patients 2004-2010. BMC Nephrol 2013;14:264. [PMID: 24289058 DOI: 10.1186/1471-2369-14-264] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
516 van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011;8:485-93. [PMID: 21629210 DOI: 10.1038/nrcardio.2011.77] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 11.0] [Reference Citation Analysis]
517 Kalra PA. Introducing iron isomaltoside 1000 (Monofer®)-development rationale and clinical experience. NDT Plus 2011;4:i10-3. [PMID: 27045417 DOI: 10.1093/ndtplus/sfr042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
518 Hu X, Xie J, Chen N. Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia. Kidney Dis (Basel) 2021;7:1-9. [PMID: 33614728 DOI: 10.1159/000510587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
519 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
520 Macciò A, Madeddu C. Management of anemia of inflammation in the elderly. Anemia 2012;2012:563251. [PMID: 23091709 DOI: 10.1155/2012/563251] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
521 Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014;29:263-73. [PMID: 24235084 DOI: 10.1093/ndt/gft443] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
522 Toor MR, Singla A, Kim JK, Sumin X, DeVita MV, Michelis MF. Preventing the progression of chronic kidney disease: two case reports and review of the literature. Int Urol Nephrol 2014;46:2167-74. [PMID: 24948202 DOI: 10.1007/s11255-014-0762-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
523 Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012;31:2973-84. [PMID: 22711298 DOI: 10.1002/sim.5403] [Cited by in Crossref: 247] [Cited by in F6Publishing: 216] [Article Influence: 24.7] [Reference Citation Analysis]
524 Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013;15:1267-76. [PMID: 23787722 DOI: 10.1093/eurjhf/hft099] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 10.4] [Reference Citation Analysis]
525 Lim SK, Goh BL, Visvanathan R, Kim SH, Jeon JS, Kim SG, Chang JH, Lim CS, Morad Z. A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure. BMC Nephrol 2021;22:391. [PMID: 34823497 DOI: 10.1186/s12882-021-02601-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Kestenbaum B. Con: Phosphate binders in chronic kidney disease. Nephrol Dial Transplant 2016;31:189-94. [PMID: 26681747 DOI: 10.1093/ndt/gfv406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
527 Chertow GM, Mahaffey KW. Venous thromboembolism: yet another cardiovascular complication of chronic kidney disease? Circulation 2012;126:1937-8. [PMID: 23071175 DOI: 10.1161/CIRCULATIONAHA.112.138057] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
528 Lundby C, Ponte B, Lundby AK, Robach P, de Seigneux S. Red blood cell volume is not decreased in ESA-naive anemic chronic kidney disease patients. Physiol Rep 2018;6:e13900. [PMID: 30426716 DOI: 10.14814/phy2.13900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
529 Califf RM. The new era of clinical research: using data for multiple purposes. Am Heart J 2014;168:133-4. [PMID: 25066550 DOI: 10.1016/j.ahj.2014.04.014] [Reference Citation Analysis]
530 Shavit L, Hitti S, Silberman S, Tauber R, Merin O, Lifschitz M, Slotki I, Bitran D, Fink D. Preoperative hemoglobin and outcomes in patients with CKD undergoing cardiac surgery. Clin J Am Soc Nephrol. 2014;9:1536-1544. [PMID: 24993450 DOI: 10.2215/cjn.00110114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
531 Lau BC, Ong KY, Yap CW, Vathsala A, How P. Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study. Springerplus 2015;4:233. [PMID: 26155438 DOI: 10.1186/s40064-015-1001-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
532 Bennett CL, Hoque S, Olivieri N, Taylor MA, Aboulafia D, Lubaczewski C, Bennett AC, Vemula J, Schooley B, Witherspoon BJ, Godwin AC, Ray PS, Yarnold PR, Ausdenmoore HC, Fishman M, Herring G, Ventrone A, Aldaco J, Hrushesky WJ, Restaino J, Thomsen HS, Yarnold PR, Marx R, Migliorati C, Ruggiero S, Nabhan C, Carson KR, McKoy JM, Yang YT, Schoen MW, Knopf K, Martin L, Sartor O, Rosen S, Smith WK. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine 2021;31:100693. [PMID: 33554084 DOI: 10.1016/j.eclinm.2020.100693] [Reference Citation Analysis]
533 Jablonski KL, Chonchol M. Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000Prime Rep 2014;6:72. [PMID: 25165571 DOI: 10.12703/P6-72] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
534 Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Front Physiol 2018;9:1294. [PMID: 30294279 DOI: 10.3389/fphys.2018.01294] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
535 Birdwell KA, Park M. Post-Transplant Cardiovascular Disease. Clin J Am Soc Nephrol 2021:CJN. [PMID: 34556500 DOI: 10.2215/CJN.00520121] [Reference Citation Analysis]
536 Covic A, Jackson J, Hadfield A, Pike J, Siriopol D. Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney Disease. Adv Ther 2017;34:1662-72. [PMID: 28578500 DOI: 10.1007/s12325-017-0566-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
537 Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301. [PMID: 23438972 DOI: 10.1038/nrneph.2013.21] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
538 Seliger S, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker L, Chiou CF, Fink JC. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol. 2010;5:882-888. [PMID: 20299377 DOI: 10.2215/cjn.07171009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
539 Ishii T, Tanaka T, Nangaku M. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. Ther Clin Risk Manag 2021;17:155-63. [PMID: 33628028 DOI: 10.2147/TCRM.S293879] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
540 Streja E, Park J, Chan TY, Lee J, Soohoo M, Rhee CM, Arah OA, Kalantar-Zadeh K. Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. Int J Nephrol 2016;2016:6087134. [PMID: 27298736 DOI: 10.1155/2016/6087134] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
541 Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2016;27:2205-15. [PMID: 26582402 DOI: 10.1681/ASN.2015060673] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
542 Thompson A. Proteinuria as a surrogate end point--more data are needed. Nat Rev Nephrol 2012;8:306-9. [PMID: 22391455 DOI: 10.1038/nrneph.2012.43] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
543 Imamura T, Ueno Y, Kinugawa K. Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure. J Cardiovasc Dev Dis 2021;8:189. [PMID: 34940544 DOI: 10.3390/jcdd8120189] [Reference Citation Analysis]
544 Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 2010;33:2310-3. [PMID: 20798337 DOI: 10.2337/dc10-0917] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
545 House AA, Haapio M, Lassus J, Bellomo R, Ronco C. Pharmacological management of cardiorenal syndromes. Int J Nephrol 2011;2011:630809. [PMID: 21660311 DOI: 10.4061/2011/630809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
546 Povsic TJ, Sloane R, Pieper CF, Pearson MP, Peterson ED, Cohen HJ, Morey MC. Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. J Gerontol A Biol Sci Med Sci 2016;71:362-9. [PMID: 26511012 DOI: 10.1093/gerona/glv180] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
547 Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant 2010;25:3701-6. [PMID: 20507852 DOI: 10.1093/ndt/gfq287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
548 Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. J Clin Pharmacol 2020;60:1432-40. [PMID: 32603526 DOI: 10.1002/jcph.1648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
549 Udell JA, Scirica BM, Braunwald E, Raz I, Steg PG, Davidson J, Hirshberg B, Bhatt DL. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clin Cardiol 2012;35:722-9. [PMID: 22760763 DOI: 10.1002/clc.22032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
550 Hayashi T, Kimura T, Yasuda K, Obi Y, Sasaki K, Iio K, Miyasato K, Kamimura T, Kitamura H, Tsubakihara Y, Rakugi H, Isaka Y. Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents. Clin Exp Nephrol 2013;17:294-303. [PMID: 23100176 DOI: 10.1007/s10157-012-0705-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
551 Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, Kshirsagar AV. Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int 2011;80:992-9. [PMID: 21849972 DOI: 10.1038/ki.2011.247] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
552 Sanghani NS, Haase VH. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Adv Chronic Kidney Dis 2019;26:253-66. [PMID: 31477256 DOI: 10.1053/j.ackd.2019.04.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 31.5] [Reference Citation Analysis]
553 Evangelista I, Nuti R, Picchioni T, Dotta F, Palazzuoli A. Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. Int J Mol Sci 2019;20:E3264. [PMID: 31269778 DOI: 10.3390/ijms20133264] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
554 Massy ZA, Drueke TB. The evolving science of anemia management in chronic kidney disease. Kidney Int Suppl (2011) 2021;11:1-2. [PMID: 33777491 DOI: 10.1016/j.kisu.2020.11.002] [Reference Citation Analysis]
555 Lentini S, van der Mey D, Kern A, Thuss U, Kaiser A, Matsuno K, Gerisch M. Absorption, distribution, metabolism and excretion of molidustat in healthy participants. Basic Clin Pharmacol Toxicol 2020;127:221-33. [PMID: 32248614 DOI: 10.1111/bcpt.13409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
556 Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 2010;299:F1-13. [PMID: 20444740 DOI: 10.1152/ajprenal.00174.2010] [Cited by in Crossref: 183] [Cited by in F6Publishing: 167] [Article Influence: 15.3] [Reference Citation Analysis]
557 Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int 2017;21 Suppl 1:S6-S20. [PMID: 28296010 DOI: 10.1111/hdi.12542] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 20.6] [Reference Citation Analysis]
558 Kurata Y, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia. Ann Transl Med 2019;7:S334. [PMID: 32016052 DOI: 10.21037/atm.2019.09.118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
559 Brătescu LO, Bârsan L, Gârneaţă L, Stanciu A, Lipan M, Stancu SH, Mircescu G. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. Int Urol Nephrol 2014;46:1005-12. [PMID: 24800994 DOI: 10.1007/s11255-014-0696-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
560 Yarnoff BO, Hoerger TJ, Simpson SA, Pavkov ME, Burrows NR, Shrestha SS, Williams DE, Zhuo X. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. PLoS One 2016;11:e0157323. [PMID: 27404556 DOI: 10.1371/journal.pone.0157323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
561 Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Meyer K, Boulware LE; DEcIDE Network Patient Outcomes in End-Stage Renal Disease Study Investigators. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant 2015;30:667-75. [PMID: 25366328 DOI: 10.1093/ndt/gfu349] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
562 Wright DG, Wright EC, Narva AS, Noguchi CT, Eggers PW. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol 2015;10:1822-30. [PMID: 26358266 DOI: 10.2215/CJN.01590215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
563 Vera-Aviles M, Vantana E, Kardinasari E, Koh NL, Latunde-Dada GO. Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. Pharmaceuticals (Basel) 2018;11:E111. [PMID: 30347874 DOI: 10.3390/ph11040111] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
564 Picon PD, Pribbernow SC, Prompt CA, Schacher SC, Antunes VV, Mentz BP, Oliveira FL, Souza CM, Schacher FC. Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. Clinics (Sao Paulo) 2014;69:547-53. [PMID: 25141114 DOI: 10.6061/clinics/2014(08)08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
565 Kengne AP, Czernichow S, Hamer M, Batty GD, Stamatakis E. Anaemia, haemoglobin level and cause-specific mortality in people with and without diabetes. PLoS One 2012;7:e41875. [PMID: 22876293 DOI: 10.1371/journal.pone.0041875] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
566 Kurella Tamura M, Meyer JB, Saxena AB, Huh JW, Wadley VG, Schiller B. Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis. Neurology 2012;79:981-7. [PMID: 22875090 DOI: 10.1212/WNL.0b013e31826845e9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
567 Eckardt KU, Agarwal R, Farag YM, Jardine AG, Khawaja Z, Koury MJ, Luo W, Matsushita K, McCullough PA, Parfrey P, Ross G, Sarnak MJ, Vargo D, Winkelmayer WC, Chertow GM. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant 2021;36:2039-48. [PMID: 33188693 DOI: 10.1093/ndt/gfaa204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
568 Alushi B, Jost-Brinkmann F, Kastrati A, Cassese S, Fusaro M, Stangl K, Landmesser U, Thiele H, Lauten A. High-Sensitivity Cardiac Troponin T in Patients with Severe Chronic Kidney Disease and Suspected Acute Coronary Syndrome. J Clin Med 2021;10:4216. [PMID: 34575325 DOI: 10.3390/jcm10184216] [Reference Citation Analysis]
569 Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol 2016;27:1234-44. [PMID: 26494831 DOI: 10.1681/ASN.2014111139] [Cited by in Crossref: 100] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
570 Kim Y, Matsushita K, Sang Y, Grams ME, Skali H, Shah AM, Hoogeveen RC, Solomon SD, Ballantyne CM, Coresh J. Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2015;65:550-8. [PMID: 25446023 DOI: 10.1053/j.ajkd.2014.08.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
571 Hanafusa N, Nomura T, Hasegawa T, Nangaku M. Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrol Dial Transplant 2014;29:2316-26. [PMID: 25150218 DOI: 10.1093/ndt/gfu272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
572 Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer 2011;117:3641-9. [PMID: 21656514 DOI: 10.1002/cncr.25972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
573 Ogoshi Y, Matsui T, Mitani I, Yokota M, Terashita M, Motoda D, Ueyama K, Hotta T, Ito T, Hase Y, Fukui K, Deai K, Yoshiuchi H, Ito S, Abe H. Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. ACS Med Chem Lett 2017;8:1320-5. [PMID: 29259755 DOI: 10.1021/acsmedchemlett.7b00404] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
574 Volpe M, Santolamazza C, Mastromarino V. Erythropoiesis-stimulating agents in heart failure: leave it or re-take it? Eur J Heart Fail 2015;17:1089-90. [PMID: 26531211 DOI: 10.1002/ejhf.432] [Reference Citation Analysis]